WO2012043633A1 - 優性変異遺伝子発現抑制剤 - Google Patents
優性変異遺伝子発現抑制剤 Download PDFInfo
- Publication number
- WO2012043633A1 WO2012043633A1 PCT/JP2011/072187 JP2011072187W WO2012043633A1 WO 2012043633 A1 WO2012043633 A1 WO 2012043633A1 JP 2011072187 W JP2011072187 W JP 2011072187W WO 2012043633 A1 WO2012043633 A1 WO 2012043633A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- dominant
- rnai
- mutant
- rnai molecule
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Definitions
- the present invention relates to a dominant mutant gene expression inhibitor comprising an RNAi molecule capable of selectively and effectively suppressing the expression of a dominant mutant gene, a pharmaceutical composition comprising the expression inhibitor, and the design of the RNAi molecule Regarding the method.
- Functional nucleic acids include siRNA (small interfering RNA), shRNA (short hairpin miRNA), miRNA (micro ⁇ ⁇ ⁇ RNA) and miRNA (micro RNA) that suppress the expression of target genes after transcription by gene silencing via RNAi (RNA interference) Decoy sequences such as nucleic acid aptamers that specifically bind to target substances such as transcription factors and suppress their functions, antisense nucleic acids that bind to target mRNAs and suppress their translation, and transcription factor binding domains Decoy DNA that suppresses gene expression by its transcription factor by capturing the target substance, specifically destabilizes the polyadenylation in the mRNA precursor of the target gene, then leads to degradation U1 adapter etc. are known. Both are expected as next-generation pharmaceuticals or diagnostic agents, but RNAi by siRNA or shRNA can suppress the desired gene expression because of its target specificity, wide applicability, and certainty of action and effect. It is in the limelight as a powerful gene expression control tool.
- RNAi Allele-specific RNAi (ASP-RNAi), an application of RNAi that can specifically suppress the expression of a desired allele, causes disease without affecting the expression of wild-type genes Since it can specifically suppress the expression of the target dominant mutation gene, it is considered to be extremely useful in the treatment of diseases.
- ASP-RNAi Allele-specific RNAi
- refractory progressive ossifying fibrodysplasia (Fibrodysplasia Ossificans Progressiva: FOP), known as one of the autosomal dominant genetic diseases, is ALK2 (Activin-like kinase 2: Activin-like kinase 2) ) It is caused by a point mutation in which 617th G (guanine) on the gene is replaced with A (adenine) or a point mutation in which the 1067th G is replaced with A. Since a mutant gene having any of these point mutations is dominant, FOP develops even in a heterozygote having a wild-type ALK2 gene (Non-Patent Documents 1 to 3).
- ASP-RNAi can suppress only the expression of the dominant mutant gene and allow the expression of the wild type gene, it can suppress the onset of autosomal dominant genetic diseases such as FOP. If the patient has already developed symptoms, the progression can be prevented.
- ASP-RNAi is particularly useful as a pharmaceutical or diagnostic agent among RNAi.
- RNAi based on the conventional general design method
- the molecule has low specificity for the mutated gene and suppresses the expression of the wild type gene.
- RNAi designed by the conventional method Molecules are not necessarily highly specific for mutant genes, and often can suppress the expression of wild-type genes.
- the design region is necessarily limited because the surrounding base sequence including the mutation site (substitution site, deletion site, insertion site, etc.) must be the target region. The Therefore, there is a problem that even if a known effective siRNA target sequence selection method is applied, it is not always possible to design a highly specific and effective siRNA.
- the present invention allows the expression of a wild-type gene or a desired dominant mutant gene, and can selectively and effectively suppress only the expression of a specific target dominant mutant gene that produces a discontinuous junction on the transcript.
- An object of the present invention is to develop an RNAi molecule and provide a dominant mutant gene expression inhibitor containing the molecule as an active ingredient and a method for designing the RNAi molecule.
- An object of the present invention is to provide a therapeutic agent for treating a hereditary disease caused by expression of a dominant mutant gene.
- RNAi molecules set so that the base length from the 3 ′ side of the sense strand region adjacent to the discontinuous junction to the 3 ′ end thereof is a predetermined length, selectively expresses the dominant mutant gene, And while suppressing effectively, it became clear that the suppression effect was hardly shown or reduced with respect to the expression of a wild-type gene.
- the present invention has been completed based on the above findings and provides the following.
- RNAi molecule is siRNA
- RNAi molecule is shRNA
- the mutation in the dominant mutation gene is selected from the group consisting of base deletion, base insertion, base replacement capable of destroying the splice site, gene duplication, gene translocation, and chromosomal inversion, (1)
- the inhibitor according to any one of (5) is selected from the group consisting of base deletion, base insertion, base replacement capable of destroying the splice site, gene duplication, gene translocation, and chromosomal inversion, (1)
- the inhibitor according to any one of (5).
- the malignant neoplasm is non-small cell lung cancer and the dominant mutant gene targeted is a mutant EGFR gene, or the malignant neoplasm is colon cancer and the dominant mutant gene targeted is mutated.
- Type CTNNB1 gene malignant neoplasm is gastric cancer and the dominant mutant gene targeted is mutant CDH1 gene, or malignant neoplasm is breast cancer and the dominant mutant gene targeted is mutated Is a type BRCA1 gene or a mutant BRCA2 gene, or the malignant neoplasm is multigland autoimmune endocrine insufficiency type I, and the dominant mutant gene that is the target is a mutant AIRE gene, or a malignant neoplasm Is an autoimmune lymphoproliferative syndrome and the dominant mutant gene targeted is a mutant TNFRSF6 / APT1 / FAS gene, or the malignant neoplasm is chronic myeloid leukemia or acute lymphocytic leukemia and the target The dominant mutant gene is a B
- the sense strand region of the RNAi molecule is SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 29, 31, 33, 35, 37, 39, 41, 43, 45 47, 49, 53, 55, 59, 61, 63, 65, 67, 129, 131, 133, 135, 137, 139, 141, 143 or 145, the suppression according to (11) Agent.
- the human autosomal dominant mutation is congenital night blindness, and the dominant mutation gene that is the target is the RHO gene, or the human autosomal dominant mutation is the deafness gene region DFNA2, and the target
- the dominant mutation gene is KCNQ4 gene or GJB gene, the human autosomal dominant mutation disease is Wardenburg syndrome, and the target dominant mutation gene is MITF gene, or the human autosomal dominant mutation disease is not Symptomatic hearing loss and the target dominant mutant gene is DIAPH1 / DFNA1 gene or POU4F3 gene, or human autosomal dominant mutation is hypertrophic cardiomyopathy, and the target dominant mutant gene is TNNT2
- the human autosomal dominant mutation is familial hypertrophic cardiomyopathy and the dominant mutation gene targeted by it is the MYBPC3 gene
- the autosomal dominant mutation is apical hypertrophic cardiomyopathy
- the target dominant mutation is the TNNI3 gene
- the human autosomal dominant mutation is Charcot-Marie-Tooth disease type 1A and its target
- the disease is myotonic dystrophy and the dominant mutant gene targeted is DMPK gene, or the disease is spinal muscular atrophy and the dominant mutant gene targeted is SMN1 gene Or the disease is congenital myasthenia syndrome and the dominant mutant gene targeted is the CHRNE gene, or the disease is frontotemporal dementia and the dominant mutant gene targeted is the MAPT gene Or the suppressor according to (8), wherein the disease is growth hormone-only deficiency type II and the dominant mutant gene targeted by the disease is the GH1 gene.
- a pharmaceutical composition comprising at least one inhibitor according to any one of (1) to (17) as an active ingredient.
- RNAi molecule having a sense strand region consisting of nucleotides represented by SEQ ID NO: 83 or 85, and / or an expression vector operably linked to a DNA encoding the RNAi molecule, and / or a sense strand region Further comprising, as an active ingredient, an RNAi molecule consisting of the nucleotide shown in SEQ ID NO: 89 and / or an expression vector operably linked to DNA encoding the RNAi molecule, depending on (11) or (12) The pharmaceutical composition according to (18).
- RNAi molecule consisting of the nucleotide represented by SEQ ID NO: 89 and / or an expression vector operably linked to DNA encoding the RNAi molecule Inhibitor.
- RNAi molecule that selectively suppresses the expression of a dominant mutant gene having a discontinuous junction on a transcript, comprising: (a) 5 ′ adjacent to the discontinuous junction on the transcript (B) the 4th to 15th bases from the base corresponding to the second reference base to the downstream side in the transcript, (C) a base sequence comprising 16 to 30 consecutive bases including the first and second reference bases of the transcript in the dominant mutant gene And (d) setting the base sequence containing a base sequence complementary to the base sequence of the set RNAi sense strand region as the RNAi antisense strand region.
- the ASP method is the design method, wherein the ASP score is calculated from the following formula.
- ASP score [(Relative ratio of normalized expression level of normal gene treated with RNAi molecule to standardized expression level of normal gene treated with control RNAi molecule) ⁇ (Standardization of mutant gene treated with control RNAi molecule) Relative ratio of the standardized expression level of the mutant gene treated with the RNAi molecule to the expressed level]] ⁇ (1-standardization of the mutant gene treated with the RNAi molecule relative to the standardized expression level of the mutant gene treated with the control RNAi molecule Relative ratio of expression level) (In the formula, the control RNAi molecule is an RNAi molecule that does not affect the expression of the normal gene and the mutant gene) (23) The design method according to (21) or (22), wherein TT or UU is further added to the 3 ′ ends of the RNAi sense strand region and the RNAi antisense strand region.
- the expression of the target dominant mutant gene is selectively and effectively suppressed without greatly affecting the expression of the wild type gene or the dominant mutant gene other than the target. It becomes possible.
- RNAi molecule which is an active ingredient of the dominant mutant gene expression inhibitor of the present invention, it is possible to design for a dominant sudden dominant mutant gene having discontinuous junctions on any transcript that causes disease. It is possible to provide a design method with high applicability.
- the disease in a hereditary disease, can be cured by selectively suppressing the expression of the target dominant mutation gene causing the disease while maintaining the expression of the wild-type gene. Is possible.
- the solid open box (0102, 0103) indicates the coding region (0102) or all or part of the exon (0103) of the gene (0101), and the solid hatched box (0104, 0105) indicates the non-coding region of the gene (5 'Non-coding region: 0104; 3' non-coding region: 0105) and solid lines (0106, 0107) sandwiched between boxes indicate all (0106) or part (0107) of the intron.
- the region indicated by the broken line is the deletion region (0108, 0109, 0110, 0111), and the dashed white box (0108, 0112) is the deletion region (0108) or deletion exon (0112) of the coding region within the exon of the gene
- the dashed lines (0113, 0114) between the boxes indicate all (0113) or part (0114) of the deleted intron.
- An arrow (0115) indicates the transcription start point.
- A shows the wild type gene
- a ' shows the transcript of the wild type gene
- B shows the mutant gene
- B' shows the transcript of the mutant gene.
- C shows the deletion region (b region) with a broken line when mutant gene B is compared with wild-type gene A.
- the junction (J) between the region a and the region c on B ′ is a discontinuous junction.
- A shows the wild type gene
- a ' shows the transcript of the wild type gene
- B shows the mutant gene
- B' shows the transcript of the mutant gene.
- Solid open boxes (0301, 0302) indicate exons
- solid lines (0303, 0304) between boxes indicate all (0303) or part (0304) of introns
- asterisks (0305) indicate 5 'splice sites.
- a region (0306) indicated by a broken line is a deletion region in the mutated gene.
- the junction (J1) between the region derived from part (0307) of the first exon (0301) and the region derived from part of intron (0304), and the intron Two junction points (J2) between the region derived from part (0304) and the region derived from the second exon (0302) are discontinuous junction points.
- A shows the wild type gene
- a ' shows the transcript of the wild type gene
- B shows the mutant gene
- B' shows the transcript of the mutant gene
- C shows a deletion region (0406) indicated by a broken line when mutant gene B is compared with wild-type gene A.
- the junction (J) between the first exon (0401) and the third exon (0403) is a discontinuous junction in the transcript B ′ of the mutant gene.
- A shows the wild type gene
- a ' shows the transcript of the wild type gene
- B shows the mutant gene
- B' shows the transcript of the mutant gene.
- white boxes in the a region and b region indicate coding regions in exons
- hatched boxes indicate non-coding regions in exons
- c regions (shaded boxes) indicate insertion portions in mutant genes. .
- junction points (J1, J2) of the region derived from the wild-type exon a region and the region derived from the insertion part that is the c region in the transcript B ′ of the mutant gene are discontinuous junction points.
- the conceptual diagram of the structure of RNAi molecule is shown.
- the case of (A) a double-stranded RNAi molecule (siRNA) and the case of (2) a single-stranded RNAi molecule (shRNA) are shown.
- numerator of Embodiment 1 is shown.
- A A diagram showing a comparison of the base sequence and amino acid sequence around the deletion site in the wild-type EGFR gene and the deletion mutant EGFR gene del (E764-A750).
- the region surrounded by a black frame is the deletion region of this mutant EGFR gene.
- the position corresponding to the discontinuous junction in the transcript of this mutant gene is indicated by an arrowhead.
- B The EGFR-siRNA expression inhibitory effect on wild-type non-target EGFR gene and deletion mutant EGFR gene del (E764-A750) was calculated as a relative value when the luciferase activity of each siControl was 1.0.
- RNAi The luciferase activity is corrected by the expression level of ⁇ -galactosidase, which is an exogenous control that is not subject to expression suppression by RNAi.
- C ASP score values of EGFR-siRNA against wild-type non-target EGFR gene and deletion mutant EGFR gene del (E764-A750). The boundary line of the ASP score value 0.4 is indicated by a broken line.
- A A diagram showing a comparison of the base sequence and amino acid sequence around the deletion site in the wild-type EGFR gene and the deletion mutant EGFR gene del (L747-T751) -L747S.
- EGFR-siRNA expression suppression effect on wild-type non-target EGFR gene and deletion mutant EGFR gene del (L747-T751) -L747S is calculated as a relative value when the luciferase activity of each siControl is 1.0 did.
- the luciferase activity of each sample is corrected by the expression level of ⁇ -galactosidase, which is an exogenous control that is not subject to expression suppression by RNAi.
- C EGFR-siRNA ASP score values for wild-type non-target EGFR gene and deletion mutant EGFR gene del (L747-T751) -L747S.
- the boundary line of the ASP score value 0.4 is indicated by a broken line.
- A It is the figure which showed the comparison of the base sequence and amino acid sequence around a deletion site
- the region surrounded by a black frame is the deletion region of the mutant EGFR gene, and the base shown in bold in the mutant EGFR gene is the insertion base.
- C ASP score values of EGFR-siRNA against wild-type non-target EGFR gene and deletion / insertion mutant EGFR gene del (L747-E749) -A750P (G).
- the boundary line of the ASP score value 0.4 is indicated by a broken line.
- A It is the figure which showed the comparison of the base sequence and amino acid sequence around a deletion site
- the region surrounded by a black frame is the deletion region of the mutant EGFR gene, and the base shown in bold in the mutant EGFR gene is the insertion base.
- the position corresponding to the discontinuous junction in the transcript of this mutant gene is indicated by an arrowhead.
- this deletion / insertion variant there are two discontinuous junctions.
- B Inhibition of EGFR-siRNA expression against wild-type non-target EGFR gene and deletion / insertion mutant EGFR gene del (L747-E749) -A750P (A), with luciferase activity of each siControl as 1.0 Was calculated as a relative value.
- RNAi The luciferase activity of each sample is corrected by the expression level of ⁇ -galactosidase, which is an exogenous control that is not subject to expression suppression by RNAi.
- C ASP score values of EGFR-siRNA against wild-type non-target EGFR gene and deletion / insertion mutant EGFR gene del (L747-E749) -A750P (A). The boundary line of the ASP score value 0.4 is indicated by a broken line.
- BCR-ABL chimeric gene and wild expressed from the Philadelphia chromosome (reciprocal translocation between the ABL gene located on the long arm of chromosome 9 (9q34) and the BCR gene located on the long arm of chromosome 22 (22q11))
- the region surrounded by the black frame is the translocated region
- the region surrounded by the black frame is the region of the ABL gene linked to the BCR gene by translocation. It is.
- a position corresponding to a discontinuous junction in the transcript of the chimeric gene is indicated by an arrowhead.
- B The suppression effect of BCR-ABL-siRNA expression on wild-type non-target ABL gene and BCR-ABL chimeric gene was calculated as a relative value when the luciferase activity of each siControl was 1.0. The luciferase activity is corrected by the expression level of ⁇ -galactosidase, which is an exogenous control that is not subject to expression suppression by RNAi.
- C ASP score value of BCR-ABL-siRNA against wild-type non-target ABL gene and BCR-ABL chimeric gene. The boundary line of the ASP score value 0.4 is indicated by a broken line.
- BCR-ABL chimeric gene and wild type generated from the Philadelphia chromosome (reciprocal translocation between the ABL gene located on the long arm of chromosome 9 (9q34) and the BCR gene located on the long arm of chromosome 22 (22q11)) It is the figure which showed the contrast of the base sequence and amino acid sequence of a translocation site periphery sequence in a BCR gene.
- the region surrounded by a black frame is the translocated region
- the region surrounded by the black frame is the region of the BCR gene linked to the ABL gene by translocation. It is.
- a position corresponding to a discontinuous junction in the transcript of the chimeric gene is indicated by an arrowhead.
- B The expression suppression effect of BCR-ABL-siRNA against wild-type non-target BCR gene and BCR-ABL chimeric gene was calculated as a relative value when the luciferase activity of each siControl was 1.0. The luciferase activity is corrected by the expression level of ⁇ -galactosidase, which is an exogenous control that is not subject to expression suppression by RNAi.
- C ASP score value of BCR-ABL-siRNA against wild-type non-target BCR gene and BCR-ABL chimeric gene. The boundary line of the ASP score value 0.4 is indicated by a broken line.
- FIG. It is an electrophoretic diagram which shows the mutated gene-specific RNAi effect when EGFR-siRNA (si747 / 49 (A) -8D19) is introduced into PC3 cells. It is the figure which showed the cell growth inhibitory effect when EGFR-siRNA (si747 / 49-3D19) was introduce
- the base sequence of the mutant EGFR gene In the base sequence of the mutant EGFR gene, the base shown in bold is the replacement site for the mutant EGFR gene.
- B The EGFR-siRNA expression inhibitory effect on the wild-type non-target EGFR gene and substitution mutant EGFR gene T790M was calculated as a relative value when the luciferase activity of each siControl was 1.0. The luciferase activity is corrected by the expression level of ⁇ -galactosidase, which is an exogenous control that is not subject to expression suppression by RNAi.
- PC3 cell a human non-small cell lung cancer-derived cell line with mutant EGFR del (L747-E749) -A750P
- PC9 a human non-small cell lung cancer cell line with mutant EGFR del (E746-A750)
- A shows PC3 cells
- B shows PC9 cells
- C shows HeLa cells. The values in each figure are shown as relative values when the cell viability in untreated cells is 100%.
- A shows results when PC3 cells are treated with B, PC9 cells are treated with C, and HeLa cells are treated with siRNA. The values in each figure are shown as relative values when the cell viability in untreated cells is 100%.
- B From an individual group not administered with siRNA (a1 to a3), an individual group administered with siControl (b1 to b3), and an individual group administered with EGFR-siRNA (si747 / 49-3D19) (c1 to c3) , Shows a tumor derived from PC3 cells extracted 3 weeks (9 weeks of age) after administration of siRNA and the like. It is the figure which showed the time course of the tumor volume when EGFR-siRNA (si747 / 49-3D19) was administered with respect to PC3 cell transplanted subcutaneously to the nude mouse.
- ⁇ indicates that there is a significant difference (p ⁇ 0.05) compared to the tumor volume of individuals not receiving siRNA, and # indicates that there is a significant difference compared to the tumor volume of individuals receiving siControl. It shows that there is a difference (p ⁇ 0.05). It is the figure which showed the tumor wet weight when EGFR-siRNA (si747 / 49-3D19) was administered with respect to the PC3 cell transplanted subcutaneously to the nude mouse. ⁇ indicates that there is a significant difference (p ⁇ 0.05) compared to the tumor volume of individuals not receiving siRNA, and # indicates that there is a significant difference compared to the tumor volume of individuals receiving siControl. It shows that there is a difference (p ⁇ 0.05).
- A A nude mouse 3 weeks (9 weeks old) after administration of siRNA or the like to a tumor (arrow) derived from subcutaneously transplanted PC3 cells is shown.
- B PC3 cell-derived tumor extracted from each individual group (5 mice per group) at 3 weeks (9 weeks of age) after administration of siRNA or the like. It is the figure which showed the time course of the tumor volume when EGFR-siRNA (si747 / 49 (A) -8D19) was administered with respect to PC3 cell transplanted subcutaneously to the nude mouse.
- ⁇ indicates that there is a significant difference (p ⁇ 0.05) compared to the tumor volume of individuals not receiving siRNA
- # indicates that there is a significant difference compared to the tumor volume of individuals receiving siControl.
- A is the total amount of bilirubin in plasma
- B is the amount of direct bilirubin in plasma
- C is the amount of indirect bilirubin in plasma
- D is the amount of alkaline phosphatase in plasma.
- siEgfr is an EGFR-siRNA having a conventional siRNA configuration.
- the 1st Embodiment of this invention is a dominant mutant gene expression inhibitor.
- the inhibitor of the present invention contains an RNAi molecule and / or an expression vector encoding it as an active ingredient, and is characterized by selectively suppressing the expression of a dominant mutant gene.
- RNAi molecule refers to the expression of a gene through the degradation of the target dominant mutant gene transcript by inducing RNA interference in vivo. Molecules that can be silenced after transcription and before translation. As long as it is a molecule that can suppress gene expression via the RNAi mechanism, it may be either a single-stranded molecule or a double-stranded molecule. Examples thereof include a double-stranded molecule such as siRNA (small interfering RNA), and a single-stranded molecule such as shRNA (short hairpin RNA) or miRNA (micro RNA).
- siRNA small interfering RNA
- shRNA short hairpin RNA
- miRNA miRNA
- RNA interference For RNA interference, see, for example, Bass BL, 2000, Cell, 101, 235-238; Sharp PA, 2001, Genes Dev., 15, 485-490; Zamore PD, 2002, Science, 296, 1265-1269; Dernburg, See AF & Karpen, GH, 2002, Cell, 111,159-162.
- gene silencing after transcription via the RNAi mechanism is hereinafter referred to as “gene expression suppression”.
- RNAi molecule is composed of a nucleic acid.
- nucleic acid refers to a natural nucleic acid, a non-natural nucleic acid, and / or a nucleic acid analog.
- natural nucleic acid refers to a biological macromolecule existing in nature in which nucleotides are structural units and they are linked by phosphodiester bonds. Usually, it corresponds to RNA in which ribonucleotides having any base of adenine, guanine, cytosine and uracil are linked and / or DNA in which deoxyribonucleotides having any base of adenine, guanine, cytosine and thymine are linked. In the RNAi molecule of the present invention, it is particularly preferred that RNA is the main constituent.
- non-natural nucleic acid refers to a nucleic acid containing or consisting of a non-natural nucleotide.
- non-natural nucleotide refers to an artificially constructed or artificially chemically modified nucleotide that does not exist in nature and has similar properties and / or structures to the naturally occurring nucleotide. It refers to nucleotides or nucleotides containing nucleosides or bases having properties and / or structures similar to naturally occurring nucleosides or bases.
- Examples include abasic nucleosides, arabino nucleosides, 2′-deoxyuridines, ⁇ -deoxyribonucleosides, ⁇ -L-deoxyribonucleosides, and other nucleosides with sugar modifications. Furthermore, substituted pentasaccharide (2'-O-methylribose, 2'-deoxy-2'-fluororibose, 3'-O-methylribose, 1 ', 2'-deoxyribose), arabinose, substituted arabinose sugar; Nucleosides with substituted hexasaccharides and alpha-anomeric sugar modifications are included.
- Non-natural nucleotides also include nucleotides that include artificially constructed base analogs or artificially chemically modified bases (modified bases).
- Base analog includes, for example, 2-oxo (1H) -pyridin-3-yl group, 5-substituted-2-oxo (1H) -pyridin-3-yl group, 2-amino-6- (2 -Thiazolyl) purin-9-yl group, 2-amino-6- (2-thiazolyl) purin-9-yl group, 2-amino-6- (2-oxazolyl) purin-9-yl group and the like.
- Modified bases include, for example, modified pyrimidines (eg, 5-hydroxycytosine, 5-fluorouracil, 4-thiouracil), modified purines (eg, 6-methyladenine, 6-thioguanosine) and other heterocyclic rings. Examples include bases. Chemically modified nucleic acids and nucleic acid analogues such as methylphosphonate DNA / RNA, phosphorothioate DNA / RNA, phosphoramidate DNA / RNA, 2′-O-methyl DNA / RNA can also be included.
- nucleic acid analog refers to an artificially constructed compound having a structure and / or property similar to that of a natural nucleic acid. Examples include peptide nucleic acids (PNA: Peptide Nucleic Acid), peptide nucleic acids having a phosphate group (PHONA), cross-linked nucleic acids (BNA / LNA: Bridged Nucleic Acid / Locked Nucleic Acid), morpholino nucleic acids, and the like.
- PNA Peptide Nucleic Acid
- PONA peptide nucleic acids having a phosphate group
- BNA / LNA Bridged Nucleic Acid / Locked Nucleic Acid
- morpholino nucleic acids and the like.
- a phosphate group, a sugar and / or a base may be labeled with a nucleic acid labeling substance, if necessary.
- a nucleic acid labeling substance any substance known in the art can be used as the nucleic acid labeling substance.
- radioisotopes eg, 32 P, 3 H, 14 C
- DIG diatomaceous iotide
- biotin e.g, FITC, Texas, cy3, cy5, cy7, FAM, HEX, VIC, JOE, Rox, TET, Bodipy493 , NBD, TAMRA
- a luminescent substance for example, acridinium ester
- mutation is a physical or structural variation of a base sequence that occurs on a gene or chromosome. There are gene mutations that occur on the gene and chromosomal mutations that occur on the chromosome. In this specification, any mutation that causes the discontinuous junction point described below on the transcript of the target dominant mutation gene is used. Also good. In addition to mutations that occur in nature, mutations are artificially induced by using mutagenic agents such as ethyl methanesulfonate (EMS) and N-methyl-N'-nitro-N-nitrosoguanidine. Also included are induced mutations and mutations introduced using molecular genetic techniques.
- EMS ethyl methanesulfonate
- N-methyl-N'-nitro-N-nitrosoguanidine also included are induced mutations and mutations introduced using molecular genetic techniques.
- mutation types include mutations based on base deletions, insertions or substitutions in genes, gene duplications or translocations, or chromosomal inversions.
- “Deletion” refers to a mutation in which a part of the base sequence of the wild-type gene is lost.
- wild-type gene is a gene that exists in nature most in an allele group of homologous genes, and a protein or functional nucleic acid encoded by the gene has an original function.
- “Functional nucleic acid” is also referred to as non-coding RNA, and is RNA having various functions by itself without encoding a protein. For example, transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), microRNA (miRNA) and the like are applicable.
- the number of deletion bases and the position are not particularly limited as long as the deletion site in one gene is a site that causes a discontinuous junction on the transcript of the deletion gene.
- Deletions of about 1 to 50 bases, 1 to 40 bases, 1 to 30 bases, or 1 to 20 bases are common, but the transcription product resulting from the deletion results in a dominant mutation in the individual carrying the mutant gene.
- 70% or more, 80% or more, or 90% or more of the base sequence of the wild-type gene may be deleted.
- the deletion site in one gene as shown in FIG.
- the gene containing one or more introns as shown in FIG. 1B lacks the region (0109) containing the entire region (0112) of one or more exons that does not contain the transcription start point (0115).
- Lost may include one or more introns and / or partial regions; in FIG. 1B, the deletion site is located on both sides of one exon in addition to the entire region (0112) A part of two introns (0114), in a gene containing one or more introns, as shown in FIG.
- a part of two exons containing the entire region (0113) of at least one intron ie, Part of the 3 'side of the upstream exon
- the region (0110) between the exon and the 5 ′ part of the downstream exon is deleted, the 3 ′ part of the upstream exon and the 5 ′ of the intron located downstream of the exon as shown in FIG. 1D
- a region including a part of the side may include the entire region of one or more other exons and introns in between; in FIG. 1D, the entire region of one exon (0112) and its The entire region (0113) of one intron located on both sides and the partial region (0114) of the other intron).
- deletion of a partial region of an intron that does not include a splice site or deletion of the entire region of one or more introns does not correspond to the deletion of the present invention because no discontinuous junction is formed on the transcript.
- “Insertion” refers to a mutation in which one or more bases are inserted into the base sequence of a wild-type gene.
- the position of insertion of a base in a gene is not particularly limited as long as it is within an exon.
- the intron when inserted into an intron, the intron is usually removed by splicing after gene expression and does not produce a discontinuous junction on the transcript. Therefore, in principle, the insertion of a base into an intron is not included in the insertion of the present invention. However, even in the insertion of an intron, if the splice site described later is destroyed by the insertion, the intron is not removed normally by splicing due to the large number of inserted bases, or inserted.
- a discontinuous junction is formed on the transcript. It shall be included in the insertion.
- the number of inserted bases is not particularly limited. For example, it may be a single base insertion as described above, or may be an insertion of several hundred bases or more like a transposon.
- substitution refers to a mutation in which the base of the wild-type gene is replaced with another base.
- substitution mutation normally, when the wild type gene and the mutant gene are compared, there is no gap between the base sequences of both genes and their transcription products. Therefore, except for substitutions that can destroy the splice site, it is usually not possible to produce discontinuous junctions on the transcript of the gene.
- substitution can destroy the splice site, removal of the intron under the control of the splice site by splicing is inhibited, resulting in a discontinuous junction on the transcript, that is, as described later.
- a gap is generated between the nucleotide sequences of the transcription product of the wild type gene and the mutant gene.
- the substitution in the present invention covers only substitution that can destroy the splice site.
- the splice site here refers to a site necessary for normal splicing in the gene sequence.
- a 5 'splice site located around the 5' end of the intron
- a 3 'splice site located around the 3' end of the intron
- the intron A general part located at a predetermined position in the intron, such as a branch point located at, corresponds.
- other bases in introns required for splicing and bases located in exons are also included.
- a base essential for formation of a higher-order structure in an RNA sequence necessary for splicing corresponds.
- the number of bases to be substituted is not particularly limited as long as the splice site can be destroyed.
- it may be a single base substitution point mutation.
- “Duplicate” refers to a mutation in which multiple identical genes exist in a chromosome. Usually, gene duplication occurs with duplication of a partial region of a chromosome containing the gene. In the present invention, only a part of the gene is duplicated, and on the basis of this, the duplication that generates a gene in which a discontinuous junction is generated on the transcript is targeted.
- Translocation refers to a mutation in which part of a gene or chromosome changes its position on the same or different chromosome.
- a gene in which a discontinuous junction is generated on a transcript containing a part of the translocated gene as a result of the translocation of a part of the gene to a different position is targeted.
- the transcript is compared with any transcript of each gene that is the basis of the fusion.
- it will have discontinuous junctions.
- “Inversion” refers to a mutation in which the direction of a part of the chromosome is reversed.
- the one in which the direction of a part of a gene is reversed due to inversion and a discontinuous junction is generated on a transcript containing a part of the reversed gene is targeted.
- “Mutant gene” refers to a gene containing a base different from the base sequence of the wild-type gene.
- the mutated gene includes not only those inherently present on the chromosome but also those acquired afterward.
- the mutated gene does not need to be present in all cells constituting the individual, and may be present only in some cells, tissues, or organs. For example, in one individual, a mutant gene that does not exist in normal cells but exists only in cancer cells can be mentioned.
- mutant mutant gene refers to a mutant gene in which a trait based on the mutation is manifested as a phenotype in an individual. As a result, as long as it is a mutant gene that dominates an individual with an abnormal phenotype, it does not matter whether the protein or functional RNA encoded by the mutant gene is active.
- gain-of-function mutation gain ⁇ ⁇ of function mutation
- loss-of-function mutation loss of function mutation
- a gain-of-function mutation is a hypermorphic mutation that causes a trait that exhibits a quantitative increase (overexpression) or increased activity (constitutive active or hyperactive) in a protein.
- neomorph mutations that cause traits exhibiting functional activity
- antimorph mutations that antagonize or suppress wild-type gene-derived proteins and suppress wild-type gene expression
- loss-of-function mutation examples include an amorph mutation in which the gene has completely lost the ability to express the phenotype and a hypomorph mutation that causes a reduction in the ability to express the gene.
- loss-of-function mutations many of them are usually recessive, but in this specification, only those whose effects are dominant are considered. A gain-of-function dominant mutation is preferred.
- discontinuous junction refers to a gap of at least one base when the base sequence of a transcription product in a mutant gene is compared with the base sequence of a transcription product of a wild-type gene (this gap is a transcription product). Base sequence on the mutant gene transcript, which disrupts the continuity of the corresponding base between the mutant gene transcript and the wild-type gene transcript. This is the joint part. One or more discontinuous junctions may be present in the transcript of one mutant gene.
- This discontinuity is based on the mutation of the mutated gene.
- the mutation is a deletion of a base in one exon
- the base sequences in the regions indicated by a and c correspond, but the 3 ′ end base of the a region and the 5 ′ end of the c region in the transcript of the wild type gene.
- the continuity is lost between bases.
- the junction (J) between the 3 'terminal base of the a region and the 5' terminal base of the c region in the mutant gene transcript B ' is a discontinuous junction.
- the deletion in mutant gene B (see C where the deletion site is indicated by a broken line) is caused by a partial base at the 3 ′ end side of the first exon (0301) and the first intron.
- the region (0306) consisting of a part of the base on the 5 ′ end side of (0303)
- a transcript B ′ containing a part of the base (0304) on the 3 ′ end side of the first intron (0303) is generated.
- the 5 'side is the base at the 3' deletion end of the first exon (0301) and the 3 'side is the first.
- the base at the 5 ′ end of 2 exons (0302) disrupts its continuity. Therefore, in this case, the base at the 3 ′ deletion end of the first exon (0301) and the base at the 5 ′ deletion end of the first intron (0304) in which a part of the 5 ′ end is truncated.
- Two discontinuous junctions are formed at the junction (J2) of the base (J1) and the base at the 3 ′ end of the first intron (0304) and the base at the 5 ′ end of the second exon (0302).
- the deletion in mutant gene B (see C where the deletion site is indicated by a broken line) is caused by a partial base on the 3 ′ end side of the first intron (0404) and the second exon ( 0402), the deletion of the 3 'splice site (0407) of the first intron of mutant gene B causes a deletion of the second exon (0402). ) Part of the 3 'terminal side (0408) is removed by splicing, and the transcript B' may be in a state where the first exon (0401) and the third exon (0403) are linked. is there.
- the junction (J) between the base at the 3 'end of the first exon (0401) and the base at the 5' end of the third exon (0403) is a discontinuous junction.
- transcript B ′ of mutant gene B containing the inserted c region and the wild type
- transcript B ′ When comparing the base sequence of the gene A with the transcript A ′, the 3 ′ end of the a region and the 5 ′ end of the c region and the 3 ′ end of the c region and the 5 ′ end of the b region in the transcript B ′
- the continuity is lost.
- junction (J1) of the 3 ′ end base of the a region and the 5 ′ end base of the c region and the 3 ′ end base of the c region and the 5 ′ end of the b region in the transcript B ′ of the mutant gene Two locations of the terminal base junction (J2) are discontinuous junctions.
- the type of target gene and the biological species from which the gene is derived are not particularly limited.
- a gene encoding any protein or functional nucleic acid can be the target of the inhibitor of this embodiment.
- the biological species may be any of animals and plants, and includes all kinds thereof. If it is an animal, it is preferably a vertebrate, more preferably a fish, a bird or a mammal. More preferably among fish species, fish species for fishery resources (for example, salmonaceae, perch, cod, herring, flounder, flatfish, horse mackerel, sandfish, Thai, and rockfish) .
- edible species for example, chickens, geese, ducks, ducks, ducks, turkeys, quails, ostriches, etc.
- edible species for example, chickens, geese, ducks, ducks, ducks, turkeys, quails, ostriches, etc.
- domestic animals pigs, cattle, sheep, goats, horses
- laboratory animals rodents, rabbits, dogs, monkeys
- competing horses pet animals (dogs, cats, rabbits, monkeys) Rodents) or humans.
- a more preferred species is human.
- a seed plant more preferably an angiosperm, and even more preferably an edible plant species (eg, Gramineae (eg, rice, wheat, barley, rye, corn, goryan, millet), legume ( For example, soybean, azuki bean, green pea), eggplant family (for example, tomato, eggplant, potato, pepper, pepper), convolvulaceae family (for example, sweet potato), rose family (for example, strawberry, almond, peach, plum, plum, rose) , Sakura), Brassicaceae (for example, Japanese radish, turnip, Brassica), Rabbitaceae (for example, spinach, sugar beet), Apiaceae, Tadeidae, Cucurbitaceae, Asteraceae, Lilyaceae, Araceae, Grapeaceae, Citrus, Edible plant species belonging to the family Beech, Palmaceae, etc.), plant species for textile resources (eg cotton, a plant species, eg, a seed plant, more
- the trait involving the mutation is not particularly limited, but is preferably a trait whose expression is to be suppressed.
- mutations involved in the onset of diseases, mutations involved in abnormal forms, and the like can be mentioned.
- the diseases referred to here include, for example, diseases caused by mutations acquired in genomic DNA in specific cells and autosomal dominant mutation diseases.
- neoplasms tumors
- malignant neoplasms malignant tumors, so-called cancers, including leukemia
- EGFR epidermal growth factor receptor
- NSCLC Small cell lung cancer
- CTNNB1 colorectal cancer caused by mutations in the CTNNB1 gene
- gastric cancer caused by mutations in the CDH1 gene gastric cancer caused by mutations in the CDH1 gene
- breast cancer caused by mutations in the BRCA1 or BRCA2 genes and many causes caused by mutations in the AIRE gene
- examples include glandular autoimmune endocrine insufficiency type I, autoimmune lymphoproliferative syndrome caused by mutations in the TNFRSF6 / APT1 / FAS gene.
- a more specific example of a malignant neoplasm caused by a mutation of a gene with a translocation that is acquired in the genomic DNA in a specific cell is caused by a chimeric gene of the BCR gene and the ABL gene.
- CML Chronic myeloid leukemia
- ALL acute lymphoblastic leukemia
- Burkitt lymphoma caused by a chimeric gene of c-myc gene and IgH gene, undifferentiated type caused by a chimeric gene of NPM gene and ALK gene
- the disease involves splicing abnormalities, myotonic dystrophy caused by mutations in the DMPK gene, spinal muscular atrophy caused by mutations in the SMN1 gene, congenital myasthenia caused by mutations in the CHRNE gene Syndrome, frontotemporal lobe dementia caused by mutation of MAPT gene, growth hormone single deficiency type II caused by mutation of GH1 gene, and the like.
- RNAi molecule contained in the inhibitor of the present embodiment comprises an RNAi sense strand region containing at least one discontinuous junction generated on the transcription product of the target dominant mutant gene, and a base sequence complementary thereto
- An RNAi antisense strand region comprising
- RNAi molecules include double-stranded molecules (FIG. 6A) or single-stranded molecules (FIG. 6B).
- RNAi sense strand region and a circular molecule for example, a dumbbell nucleic acid
- a dumbbell nucleic acid for example, a dumbbell nucleic acid
- RNAi molecules contained in the inhibitor of the present embodiment has an RNAi sense strand region (0601), an RNAi antisense strand region (0602), and a discontinuous junction (0603) as essential components. Include as. Hereinafter, components common to RNAi molecules will be described.
- the “RNAi sense strand region” (0601) is composed of a base sequence that matches the base sequence of the transcription product of the target dominant mutant gene, and a discontinuous junction (0603) that occurs on the transcription product (sense in FIG. 6).
- the chain region (0601) includes at least one of the hatched region and the white region.
- the base length of the sense strand region (0601) is 16 to 30 bases, 18 to 25 bases, or 19 to 23 bases of the transcript.
- the 3 ′ base (0604) adjacent to the discontinuous junction (0603) is used as a reference (corresponding to a second reference base described later), and 3 to 16 from the reference base toward the downstream side.
- the 3rd base preferably 4th to 15th base (0605), more preferably 4th to 13th base constitutes the 3 ′ terminal base of the RNAi sense strand region.
- the 3 ′ base adjacent to any one of the discontinuous junctions may be used as the reference base.
- the “RNAi antisense strand region” (0602) is composed of a base sequence that is completely complementary to the RNAi sense strand region (0601). Therefore, the base sequence includes a base (0607) complementary to the reference base, that is, the 3 'base adjacent to the discontinuous junction (0603).
- the RNAi molecule of this embodiment is a double-stranded molecule (FIG. 6A)
- the RNAi antisense strand region is contained in the other polynucleotide strand different from the polynucleotide strand containing the RNAi sense strand region.
- FIG. 6B double-stranded molecule it is contained in the reverse direction in the same polynucleotide chain as the RNAi sense strand region.
- RNAi molecule of this embodiment is characterized by having an ASP score value of 0.4 or more.
- ASP score Allele-SPecificity score
- ASP score value is a quantification of allele discrimination ability, which is an important element in ASP-RNAi, and further suppresses non-specific expression of RNAi molecules against normal genes. It can also be considered that the effect of RNAi molecules, that is, the side effects of RNAi molecules on normal genes are quantified.
- the ASP score value is derived by the following formula.
- ASP score [(Relative ratio of normalized expression level of normal gene treated with RNAi molecule to standardized expression level of normal gene treated with control RNAi molecule) ⁇ (Standardization of mutant gene treated with control RNAi molecule) Relative ratio of the standardized expression level of the mutant gene treated with the RNAi molecule to the expressed level]] ⁇ (1-standardization of the mutant gene treated with the RNAi molecule relative to the standardized expression level of the mutant gene treated with the control RNAi molecule Relative ratio of expression level)
- the control RNAi molecule is an RNAi molecule that is a negative control of the siRNA molecule that is the active ingredient of the present embodiment, and is an RNAi molecule that does not affect the expression of the normal gene and the mutant gene.
- the expression level of the normalized gene treated with the control RNAi molecule is considered as 100%.
- an RNAi molecule containing an arbitrary base sequence that does not have a target gene is applicable.
- the relative ratio of the expression level after standardization exceeds “1.0”, it is considered that there is no expression suppression effect, and the relative ratio is calculated as “1.0”.
- the ASP score can reflect both “specificity” and “suppression effect” for mutant genes. For example, if an RNAi molecule has a low ASP score, even if the RNAi molecule can strongly suppress the expression of the mutant gene, it also strongly suppresses the expression of the wild-type gene at the same time because of its low specificity. Meaning that there are strong side effects on wild-type genes. If the ASP score value is 0.4 or more, the RNAi molecule functions as ASP-RNAi because it suppresses the expression of the mutated gene and has no or a relatively weak effect on the wild-type gene. obtain.
- any method known in the art may be used as long as each expression level is measured by the same method. Not limited. Standardization may be performed based on the expression level of an internal or exogenous control gene that is not subject to expression suppression by RNAi molecules. Preferably, using a reporter gene expression plasmid developed by Ohnishi Y. et al. (2006, Journal of RNAi and Gene Silencing, Vol.
- Example 2 Based on the expression of a reporter gene such as Renilla luciferase and the expression of a ⁇ -galactosidase gene that is not subject to expression suppression by RNAi molecules as a control, the expression levels of the wild type gene and the mutant gene are measured.
- a reporter gene such as Renilla luciferase
- a ⁇ -galactosidase gene that is not subject to expression suppression by RNAi molecules
- RNAi molecules contained in the inhibitor of this embodiment is a double-stranded molecule such as siRNA, as shown in FIG. 6A
- the RNAi sense strand region (0601), RNAi antisense, which is a common component of the RNAi molecule is used.
- it may optionally further comprise a 3 ′ terminal added base (0606) at the 3 ′ end of each polypeptide chain.
- the “3 ′ terminal addition base” (0606) is composed of two bases of TT (thymine-thymine) or UU (uracil-uracil).
- RNAi molecules to which this base has been added can increase RNAi suppression efficiency (Tuschl T et al., 1999, Genes Dev, 13 (24): 3191-7).
- RNAi molecule contained in the inhibitor of this embodiment is a single-stranded molecule such as shRNA, as shown in FIG. 6B, the RNAi sense strand region (0601), which is a common component of the RNAi molecule, and RNAi antisense In addition to the strand region (0602) and the discontinuous junction (0603), a short spacer sequence (0608) linking the RNAi sense strand region (0601) and the opposite RNAi antisense strand region (0602). including.
- the spacer sequence can be any base sequence usually comprising 3 to 24 bases, preferably 4 to 15 bases.
- the whole molecule consists of 35 bases (16 ⁇ 2 + 3) to 84 bases (30 ⁇ 2 + 24).
- the RNAi sense strand region and the RNAi antisense strand region are base paired with each other, and the spacer sequence located between them forms a loop structure, so that the entire molecule can have a hairpin-type stem-loop structure. .
- RNAi molecule having the above structure When a single-stranded RNAi molecule having the above structure is introduced into a cell, it is processed into a double-stranded siRNA by the action of an endonuclease called Dicer in the cytoplasm, of which the RNAi antisense strand region is RNA-induced silencing. complex) and then incorporated into the complex, the post-transcriptional pre-translational expression of the target gene can be suppressed by the RNAi mechanism similar to the double-stranded RNAi molecule described above.
- RNAi sense strand region (0601) and RNAi antisense strand region (0602) in a single-stranded molecule may contain a 3 'terminal added base at the 3' end of each region, as in the case of the double-stranded RNAi molecule. it can. Arbitrary sequences can be added to the 5 ′ end and / or the 3 ′ end of the single-stranded molecule. For example, a base sequence capable of forming a stem loop structure can be added to the 5 ′ end and / or the 3 ′ end.
- an “expression vector” is an active ingredient contained in the inhibitor of the present embodiment, and is inserted into an expression vector so that the DNA encoding the RNAi molecule can be expressed. It is a vector.
- RNAi molecule when the RNAi molecule is a double-stranded molecule such as siRNA, DNA fragments encoding each of the RNAi sense strand region and the RNAi antisense strand region are inserted into two different expression vectors. It may also be inserted as a DNA fragment whose expression is independently controlled in one expression vector.
- RNAi molecule when the RNAi molecule is a single-stranded molecule such as shRNA, a DNA fragment encoding the single-stranded RNA molecule may be inserted at a predetermined position in the expression vector.
- the “expression vector” refers to the backbone part of the expression vector of this embodiment, that is, the part other than the DNA fragment encoding the RNAi molecule of Embodiment 1 in the expression vector of this embodiment.
- the type of expression vector is not particularly limited, but a plasmid or virus is preferred. These may be appropriately selected according to the host to be introduced. For example, when the host to be introduced is a human, a known expression vector such as a virus based on adenovirus, retrovirus, lentivirus, Sendai virus, adeno-associated virus, or non-viral vector is used. be able to.
- plasmids such as pBI or pRI binary vectors, cauliflower mosaic virus (CaMV), kidney bean golden mosaic virus (BGMV), and tobacco mosaic virus (TMV). can do.
- CaMV cauliflower mosaic virus
- BGMV kidney bean golden mosaic virus
- TMV tobacco mosaic virus
- plasmids such as pBI, pPZP, pSMA, pUC, pBR, and pBluescript (Stratagene) can be used.
- various expression vectors for various hosts that are commercially available from various life science manufacturers may be used.
- the expression vector may include a regulatory region such as a promoter, enhancer, or terminator, or a labeling region such as a selectable marker gene. Each type is not particularly limited. What is known in the art may be appropriately selected according to the host into which the expression vector is introduced.
- promoters operable in E. coli include lac, trp or tac promoters or phage-derived T7, T3, SP6, PR or PL promoters.
- promoters operable in yeast include promoters derived from yeast glycolytic genes, alcohol dehydrogenase gene promoters, TPI1, and ADH2-4c promoters.
- promoters operable in plant cells include cauliflower mosaic virus (CaMV) 35S promoter, nopaline synthase gene promoter (Pnos), corn-derived ubiquitin promoter, rice-derived actin promoter, tobacco-derived PR protein promoter, and the like. Can be mentioned.
- promoters operable in insect cells include polyhedrin promoter, P10 promoter, autographa calicornica polyhedrossis basic protein promoter, baculovirus immediate early gene 1 promoter, baculovirus 39K delayed early gene promoter, etc. Can be mentioned.
- a promoter operable in animal cells such as humans an RNA polymerase II (Pol II) promoter and an RNA polymerase III (Pol III) promoter are preferably used.
- Pol III promoters are preferable, and promoters such as U6 and H1 are particularly preferable.
- a site-specific promoter that induces expression only at a specific site in the living body can also be used.
- the promoters are the same so that each RNA strand is expressed in the same amount. It is preferable to use a promoter or a different promoter having the same level of expression activity.
- the present design method includes a reference base setting step (0701), a 3 ′ terminal base setting step (0702), an RNAi sense strand region setting step (0703), and an RNAi antisense strand region setting step (0704). )including.
- a reference base setting step (0701)
- a 3 ′ terminal base setting step (0702)
- an RNAi sense strand region setting step (0703)
- an RNAi antisense strand region setting step (0704).
- the “reference base setting step” (0701) means that the 5 ′ and 3 ′ bases adjacent to the discontinuous junction on the transcript in the target dominant mutant gene are the first and second reference bases, respectively. It is the process of setting as. When there are two or more discontinuous junctions in the transcript of the dominant mutant gene, one of the discontinuous junctions is selected. In that case, the 5'-side and 3'-side bases adjacent to the selected discontinuous junction are the first and second reference bases, respectively.
- the “3 ′ terminal base setting step” (0702) is the 4th to 15th base, preferably the 4th to 14th base, or the 4th to 13th base from the base corresponding to the second reference base toward the downstream side. Is a step of setting so as to correspond to the 3 ′ terminal base of the RNAi sense strand region.
- RNAi sense strand region setting step is a step of setting 16 to 30 bases including the first and second reference bases as RNAi sense strand regions in the base sequence of the transcription product of the dominant mutant gene. is there. Since the 3 ′ terminal base is determined by the 3 ′ terminal base setting step, the first of the bases of the transcription product is counted upstream from the base corresponding to the 3 ′ terminal base. In addition, 16 to 30 bases may be set as the RNAi sense strand region so as to include the second reference base. This process determines the target region for the dominant mutant gene of the RNAi molecule.
- RNAi antisense strand region setting step is a step of setting a base sequence containing a base sequence complementary to the base sequence of the set RNAi sense strand region as the RNAi antisense strand region.
- RNAi molecule contained in the inhibitor of the present embodiment (for example, a single-stranded RNAi molecule, a double-stranded RNAi molecule, or a circular RNAi molecule).
- a 3 'end addition step is characterized by adding TT (thymine-thymine) or UU (uracil-uracil) to each 3 ′ end of the RNAi sense strand region and the RNAi antisense strand region designed above. To do. Since this step is an optional step, it may be added as necessary.
- the “spacer linking step” is a unique and essential step for single-stranded RNAi molecules or circular RNAi molecules. This step is performed at the 3 ′ end of the RNAi sense strand region designed above (if the RNAi sense strand region has undergone a 3 ′ end addition step prior to this step, it is added to the 3 ′ end of the RNAi sense strand region. TT or UU 3 ′ end) and the 5 ′ end of the RNAi antisense strand region (ie, in the opposite direction to the RNAi sense strand region), respectively, are linked to the 3 ′ end and 5 ′ end of the spacer sequence, respectively. This is a step of making a double-stranded molecule or a circular RNAi molecule.
- the spacer sequence may be any base sequence consisting of 3 to 24 bases, preferably 4 to 15 bases. Preferably, the base sequence does not form base pairing in the spacer sequence.
- the “ASP score selection step” is a step of selecting only RNAi molecules having an ASP score value of 0.4 or more from the RNAi molecules prepared by the above steps.
- the ASP score may be calculated from the above formula.
- the RNAi molecule of this embodiment can be synthesized by a chemical synthesis method based on the base sequence designed by the aforementioned method.
- each life science manufacturer for example, Sigma-Aldrich, Bex, Takara Bio, Invitrogen, etc.
- the RNAi molecule of the present embodiment is obtained by converting the nucleotide sequence designed by the above method into a DNA sequence, cloning a chemically synthesized DNA based on the sequence, and then in vitro known in the art.
- RNA can be prepared by RNA transcription. For example, Sambrook, J. et.
- a method for preparing an expression vector contained in the inhibitor of the present embodiment is basically a method known in the art, for example, Sambrook, J. et. Al., (1989) Molecular Cloning: a It can be prepared according to the method described in Laboratory Manual Second Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
- the base sequence of the RNAi molecule is determined according to the method described in the above section “1-5. Design and production of RNAi molecule”. Subsequently, based on the corresponding DNA sequence, sense strand DNA and antisense strand DNA are respectively synthesized by a chemical synthesis method or the like. At this time, it is preferable that an appropriate restriction site is added to both ends of each chain, or an appropriate cohesive end is formed after annealing of each chain. As for DNA synthesis, manufacturers of life science related companies offer contract synthesis services, which can also be used. After synthesis, both strands are mixed and annealed to prepare a double-stranded DNA fragment.
- a restriction site is added to the end, it is cleaved with the restriction enzyme as necessary. Further, the 5 'end of each chain is phosphorylated with T4 polynucleotide kinase or the like as necessary. Subsequently, the prepared double-stranded DNA fragment is ligated to the corresponding restriction site downstream of the promoter of the expression vector.
- the DNA fragment may be once ligated to an appropriate cloning vector and cloned, and then the DNA fragment may be ligated to an expression vector.
- TT is inserted in advance at each 3' end of the RNAi sense strand region and the RNAi antisense strand region. Since this step is an optional step, it may be added as necessary.
- Mutant EGFR gene expression inhibitor As an example of the dominant mutant gene expression inhibitor of this embodiment, an RNAi molecule (EGFR-RNAi molecule) that specifically suppresses the expression of the mutant EGFR (epidermal growth factor receptor) gene is effective.
- a mutant EGFR gene expression inhibitor used as a component may be mentioned.
- the mutated EGFR gene referred to here is a dominant mutated gene that is acquired and is a gene that causes non-small cell lung cancer (NSCLC).
- NSCLC non-small cell lung cancer
- a ligand such as epidermal growth factor (EGF) binds to the extracellular domain of EGFR, it usually activates the tyrosine kinase in the intracellular domain and activates autophosphorylation.
- EGF epidermal growth factor
- substitution, deletion, or insertion occurs in a specific base of the EGFR gene, and it is thought that it occurs when the downstream intracellular signal transduction pathway is constitutively activated. (Paez GJ et al., Science, 2004, 304; 1497-1500).
- the mutant EGFR gene expression inhibitor of the present embodiment can specifically suppress gene expression based on mutations such as deletion and insertion other than substitution in such mutant EGFR gene.
- mutant EGFR gene expression inhibitor of the present embodiment include a part of the human EGFR gene as shown in FIGS. 8-1, 9-1, 10-1, and 11-1.
- EGFR-RNAi for each of the del (E746-A750) and del (L747-T751) -L747S mutations with deleted bases, and the del (L747-E749) -A750P mutation with deleted and inserted partial bases Examples include mutant EGFR gene expression inhibitors containing molecules as active ingredients.
- the del (L747-E749) -A750P mutation as will be described later, even if the encoded amino acid sequence is the same, the difference in G and A between the bases due to the deletion and insertion of the base sequence is different.
- del (L747-E749) -A750P mutation when it is necessary to distinguish the difference between these mutations, the mutation having G is hereinafter referred to as del (L747-E749) -A750P ( G) mutation (FIG. 10-1A), and mutation with A is del (L747-E749) -A750P (A) mutation (FIG. 11-1A).
- the sense strand region has SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17 , 19 or 21 single stranded or double stranded RNAi molecule, or an expression vector operably linked to DNA encoding the RNAi molecule.
- the sense strand region is represented by SEQ ID NO: 29, 31, 33, 35, 37, 39, 41, 43, 45, 47 or 49.
- the sense strand region is a single strand or a double strand represented by SEQ ID NO: 53, 55, 59, 61, 63, 65 or 67.
- the sense strand region is represented by SEQ ID NO: 129, 131, 133, 135, 137, 139, 141, 143 or 145.
- An expression vector in which a single-stranded or double-stranded RNAi molecule or a DNA encoding the RNAi molecule is operably linked.
- BCR-ABL chimeric gene expression inhibitor As an example of the dominant mutant gene expression inhibitor of this embodiment, an RNAi molecule (BCR-) that specifically suppresses the expression of a BCR-ABL chimeric gene caused by a translocation mutation in the Philadelphia chromosome.
- the BCR-ABL chimera gene here is an acquired dominant mutation gene, which is regarded as a causative gene of chronic myeloid leukemia (CML) or acute lymphocytic leukemia (ALL).
- CML chronic myeloid leukemia
- ALL acute lymphocytic leukemia
- the Philadelphia chromosome (Ph chromosome) is found in more than 90% of cases of chronic myelogenous leukemia (CML) and about 20% of acute lymphocytic leukemia (ALL). It is a tumor-specific chromosome with a translocated structure. As a result of this translocation, the ABL gene located on the long arm of chromosome 9 (9q34) and the BCR gene located on the long arm of chromosome 22 (22q11) reciprocally translocate to form a BCR-ABL chimeric gene. A p210 or p190 protein with enhanced tyrosine kinase activity is produced.
- the BCR-ABL chimeric gene expression inhibitor of this embodiment can specifically suppress the expression of such a BCR-ABL chimeric gene.
- a BCR-ABL-RNAi molecule for the BCR-ABL chimeric gene is used as an active ingredient.
- a BCR-ABL chimeric gene expression inhibitor More specifically, for example, the sense strand region is a single-stranded or double-stranded RNAi molecule represented by SEQ ID NO: 97, 99, 101, 103, 105, 107, 109, 111 or 113, or an RNAi molecule thereof Is an expression vector operably linked to DNA encoding.
- the RNAi molecule as an active ingredient selectively and efficiently suppresses the expression of the target gene with little effect on the expression of the non-target gene. can do.
- the inhibitor of the present embodiment when an RNAi molecule is used as an active ingredient when introduced into a cell, the RNAi molecule is left as it is, and when an expression vector is used as an active ingredient, the expression vector is added to the expression vector. After the RNAi molecule encoded by the contained DNA is expressed, it can act on the target dominant mutant gene and suppress its expression by the RNAi silencing mechanism. Therefore, when the inhibitor contains RNAi molecules, the administered effect can be imparted to the administered cells in a relatively short time. On the other hand, when the inhibitor contains an expression vector, the above effect can be continuously imparted as long as the expression vector is maintained in the cell after administration. Therefore, the combined use of these can effectively suppress the expression of the dominant mutant gene.
- composition The second embodiment of the present invention is a pharmaceutical composition.
- the pharmaceutical composition of the present invention contains the dominant mutant gene expression inhibitor of Embodiment 1 as an active ingredient.
- the dominant mutant gene expression inhibitor may contain an RNAi molecule for the target dominant mutant gene or an expression vector operably linked to the DNA encoding the RNAi molecule, or target the same gene. And / or an expression vector in which DNAs encoding one or more different RNAi molecules and / or one or more different RNAi molecules are operably linked.
- the active ingredient of the pharmaceutical composition of the present embodiment is a mutant EGFR gene expression inhibitor, and the inhibitor contains two or more different EGFR-RNAi molecules
- the del (E746-A750) mutation EGFR-RNAi molecule targeting the gene for example, the sense strand region comprises a nucleotide sequence represented by SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19 or 21
- del (L747- EGFR-RNAi molecule targeting the T751) -L747S mutant gene for example, the nucleotide sequence of which the sense strand region is represented by SEQ ID NO: 29, 31, 33, 35, 37, 39, 41, 43, 45, 47 or 49
- EGFR-RNAi molecule targeting the del (L747-E749) -A750P (G) mutant gene for example, the base whose sense strand region is represented by SEQ ID NO: 53, 55, 59, 61, 63, 65 or 67
- a mutant EGFR gene expression inhibitor is an EGFR-RNAi molecule and an EGFR-RNAi molecule expression vector (for example, operably linked DNA encoding the EGFR-RNAi molecule and / or a different EGFR-RNAi molecule) ) Can also be included.
- the pharmaceutical composition of the embodiment has other active ingredients within a pharmaceutically acceptable range and within a range in which the RNAi molecule and / or expression vector in the dominant mutant gene expression inhibitor of the first embodiment is not inactivated. So-called composite preparations that can contain
- the other active ingredients mentioned here target the same gene as the dominant mutant gene expression inhibitor of the first embodiment, but have an RNAi molecule having a configuration different from that of the active ingredient of the first embodiment and / or its RNAi.
- An expression inhibitor comprising an expression vector operably linked to DNA encoding a molecule can be used.
- an EGFR-RNAi molecule having the configuration described in Embodiment 1 and / or an expression vector in which DNA encoding the RNAi molecule is operably linked is included.
- the sense strand region includes an RNAi molecule represented by SEQ ID NO: 83 or 85 and / or an expression vector operably linked to the DNA encoding the RNAi molecule.
- the dominant allele expression inhibitor is mentioned.
- a dominant mutant gene expression inhibitor different from the above-described dominant allele expression inhibitor, wherein the sense strand region described in Example 4 to be described later is an RNAi molecule represented by SEQ ID NO: 89 and / or its RNAi molecule
- An inhibitor containing an expression vector operably linked to the encoding DNA as an active ingredient can also be contained.
- Such a combined preparation using as an active ingredient an inhibitor that suppresses the expression of a gene based on each mutation targeting different mutation sites of the same gene is useful when the mutation site of the target gene is not clear. Since the RNAi molecule, which is an active ingredient of the inhibitor, has high specificity for the target mutation gene, side effects that suppress the expression of other genes even when mixed and RNAi molecules and / or expression vectors are inactivated. It has the advantage that there is almost no possibility.
- the other active ingredient may be a drug having a pharmacological action different from that of the dominant mutant gene expression inhibitor of the first embodiment.
- antibiotics etc. are mentioned.
- the pharmaceutical composition of the present invention contains an RNAi molecule as an active ingredient and / or a medium for an expression vector.
- the medium includes, for example, solvents such as water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol and polyoxyethylene sorbitan fatty acid esters.
- solvents such as water, ethanol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol and polyoxyethylene sorbitan fatty acid esters.
- Such a medium is desirably sterilized and is preferably adjusted to be isotonic with blood as necessary.
- the content of the RNAi molecule and / or expression vector as an active ingredient in the pharmaceutical composition is the type of the causative gene of the disease to be treated, the onset action mechanism of the gene, the RNAi molecule
- the effect varies depending on various conditions such as the action effect and stability, the expression level of the expression vector, the dosage form of the pharmaceutical composition, the type of carrier used, the administration method, the condition of the subject to be administered and the like. These may be appropriately selected based on known techniques in the field.
- Specific examples of the content of the RNAi molecule or the expression vector of the present invention are as follows.
- nucleic acid When administered by injection to a human adult male (body weight 60 kg) that does not require the use of other pharmaceuticals, It may be contained at 0.01% (w / v) to about 20% (w / v), preferably about 0.1% (w / v) to about 10% (w / v). Specifically, for example, 1 ⁇ g to 200 ⁇ g of siRNA is usually contained in 1 mL injection at a time.
- the nucleic acid can be divided into several times to reduce the burden on the subject.
- the pharmaceutical composition of the present invention can further contain a pharmaceutically acceptable carrier as necessary.
- a pharmaceutically acceptable carrier refers to an additive usually used in the field of pharmaceutical technology.
- an excipient, a binder, a disintegrant, a filler, an emulsifier, a fluid addition regulator, a lubricant and the like can be mentioned.
- Excipients include sugars such as monosaccharides, disaccharides, cyclodextrins and polysaccharides (more specifically, but not limited to glucose, sucrose, lactose, raffinose, mannitol, sorbitol, inositol, dextrin, malto Dextrin, starch and cellulose), metal salts (eg sodium chloride, sodium phosphate or calcium phosphate, calcium sulfate, magnesium sulfate, calcium carbonate), citric acid, tartaric acid, glycine, low, medium and high molecular weight polyethylene glycols ( PEG), pluronic, kaolin, silicic acid, or combinations thereof.
- sugars such as monosaccharides, disaccharides, cyclodextrins and polysaccharides (more specifically, but not limited to glucose, sucrose, lactose, raffinose, mannitol, sorbitol, inos
- binders include starch paste using corn, wheat, rice, or potato starch, simple syrup, glucose solution, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, shellac and / or polyvinylpyrrolidone. As mentioned.
- Disintegrants include the starch, lactose, carboxymethyl starch, cross-linked polyvinyl pyrrolidone, agar, laminaran powder, sodium bicarbonate, calcium carbonate, alginic acid or sodium alginate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride Or their salts are mentioned as examples.
- the filler examples include the sugar and / or calcium phosphate (for example, tricalcium phosphate or calcium hydrogen phosphate).
- emulsifiers examples include sorbitan fatty acid esters, glycerin fatty acid esters, sucrose fatty acid esters, and propylene glycol fatty acid esters.
- Examples of the flow addition regulator and lubricant include silicate, talc, stearate or polyethylene glycol.
- Such a carrier mainly facilitates the formation of the dosage form and maintains the dosage form and drug effect.
- the RNAi molecule which is an active ingredient of the dominant mutant gene expression inhibitor, is subject to degradation by nucleolytic enzymes in vivo. It is used to make it difficult, and may be used as needed.
- flavoring agents, solubilizers, suspending agents, diluents, surfactants, stabilizers, absorption promoters, extenders, moisturizers, humectants, adsorbents, if necessary Disintegration inhibitors, coating agents, coloring agents, preservatives, antioxidants, fragrances, flavoring agents, sweetening agents, buffering agents and the like can also be included.
- the pharmaceutical composition of the present invention can also contain other drugs as long as the pharmacological effect of the RNAi molecule is not lost.
- a predetermined amount of antibiotics may be contained.
- the dosage form of the pharmaceutical composition of the present embodiment is not particularly limited as long as it does not inactivate RNAi molecules or expression vectors, which are active ingredients in the inhibitor, and other additional active ingredients. Since RNA is generally unstable, a dosage form that is difficult to degrade in vivo when an RNAi molecule is administered is preferred. For example, any of liquid, solid, or semi-solid may be sufficient. Specific dosage forms include, for example, parenteral dosage forms such as injections, suspensions, emulsions, eye drops, nasal drops, creams, ointments, plasters, shipping agents and suppositories, or liquids and powders. Oral dosage forms such as granules, tablets, capsules, sublinguals, lozenges and the like. In the case of the pharmaceutical composition of this embodiment containing an inhibitor comprising an RNAi molecule or an expression vector as an active ingredient, the dosage form is preferably an injection.
- the pharmaceutical composition of the present embodiment or the dominant mutant gene expression inhibitor of the first embodiment is applied to nanoparticles (for example, target nanoparticle transmission described in Davis ME, et al., Nature, 2010, 464: 1067-1070).
- nanoparticles for example, target nanoparticle transmission described in Davis ME, et al., Nature, 2010, 464: 1067-1070.
- liposomes eg, membrane-permeable peptide-bound liposomes, including SNALPs
- cholesterol conjugates eg, cholesterol conjugates.
- the RNAi transmission system described in Castanotto D. & Rossi JJ., Nature, 2009, 457, 426-433 can also be used.
- the pharmaceutical composition of the present embodiment can be administered to a living body in a pharmaceutically effective amount for the treatment of the target disease.
- the living body to be administered is a vertebrate, preferably a mammal, more preferably a human.
- the “pharmaceutically effective amount” means that the RNAi molecule and / or expression vector, which is an active ingredient of the inhibitor contained in the pharmaceutical composition of the present invention, treats the target disease or reduces the symptoms.
- Necessary dose specifically, a dose capable of suppressing the expression of the dominant mutation gene causing the disease
- harmful side effects to the administered organism eg, wild type gene
- the specific amount varies depending on the type of the target gene, the phenotypic effect of the dominant mutant gene, the dosage form to be used, information on the subject (subject in the case of a human) and the administration route.
- the pharmaceutically effective amount range and suitable route of administration is generally based on data obtained from cell culture assays and animal studies.
- the final dose is determined and adjusted according to the judgment of the doctor according to the individual subject.
- the information of the subject to be considered includes the degree or severity of the disease, the general health condition, age, weight, sex, diet, drug sensitivity, resistance to treatment, and the like.
- the RNAi molecule of the present invention may be administered systemically or locally. It can select suitably according to the kind of disease, onset location, or a progression degree. If the onset site is a local disease, local administration directly administered to and around the onset site by injection or the like is preferable. This is because a sufficient amount of the RNAi molecule of the present invention can be administered to a site (tissue or organ) to be treated and it is difficult to affect other tissues. On the other hand, when the treatment site cannot be specified as in metastatic cancer or when the onset is a systemic disease, systemic administration by intravenous injection or the like is preferable, although there is no limitation. This is because by spreading the RNAi molecule of the present invention throughout the body through the bloodstream, it can be administered even to a lesion that cannot be detected by diagnosis.
- RNAi molecule of the present invention can be administered by any suitable method that does not deactivate the active ingredient contained therein.
- it may be parenteral (for example, injection, aerosol, application, eye drop, nose drop) or oral.
- parenteral for example, injection, aerosol, application, eye drop, nose drop
- oral Preferably, it is an injection.
- the injection site is not particularly limited. Any site may be used as long as the RNAi molecule produced from the RNAi molecule of the present invention or the expression vector exhibits its function with respect to the target molecule and can achieve the purpose of the pharmaceutical composition. Examples include intravenous, intraarterial, intrahepatic, intramuscular, intraarticular, intramedullary, intrathecal, intraventricular, percutaneous, subcutaneous, intradermal, intraperitoneal, intranasal, intestinal, or sublingual. . Intravenous injection such as intravenous injection or intraarterial injection is preferable. This is because the pharmaceutical composition of the present invention can be distributed throughout the body through the blood stream as described above, and is less invasive. For example, RNAi molecules may be administered systemically by intravascular injection using the aforementioned target nanoparticle delivery system of Davis et al.
- the pharmaceutical composition of the present invention is used for the treatment of diseases.
- a disease caused by the expression of a dominant mutant gene such as an autosomal dominant genetic disease
- the wild-type gene encoding a gene protein that selectively suppresses the expression of the mutant gene and simultaneously has a normal function. Since the phenotype of the type gene can be revealed, it can be used for improvement of varieties of animals and plants, in addition to the treatment of genetic diseases and cancer that have been difficult to treat. Therefore, the disease targeted by the pharmaceutical composition of the present embodiment is a disease based on the dominant trait of the dominant mutant gene targeted by the RNAi molecule contained in the inhibitor or the RNAi molecule expressed from the expression vector.
- the pharmaceutical composition of the present embodiment can be used in various ways by using, as an active ingredient, an RNAi molecule for a dominant mutation gene that is a causative gene or an expression vector containing a DNA encoding the gene depending on the disease to be treated. Applicable to various diseases.
- EGFR-siRNA Designed siRNA (EGFR-siRNA) that specifically suppresses the expression of mutant EGFR (epidermal growth factor receptor) gene, and suppresses the expression of mutant gene (cancer-causing gene), namely ASP-RNAi (allele-specific gene) Silencing: Allele-specific RNAi) effect was verified.
- EGFR-siRNA Designed siRNA (EGFR-siRNA) that specifically suppresses the expression of mutant EGFR (epidermal growth factor receptor) gene, and suppresses the expression of mutant gene (cancer-causing gene), namely ASP-RNAi (allele-specific gene) Silencing: Allele-specific RNAi) effect was verified.
- the gain-of-function mutant EGFR gene is a causative gene of non-small cell lung cancer (NSCLC). Therefore, if the EGFR-siRNA of the present invention has an ASP-RNAi effect that specifically suppresses only the expression of such a gain-of-function mutant EGFR gene, effective treatment for non-small cell lung cancer Can be an agent.
- NSCLC non-small cell lung cancer
- mutant EGFR gene In non-small cell lung cancer patients, various mutations (gain-of-function mutations) related to the disease have been found in the EGFR gene (Accession No. NM_005228). For example, as shown in FIG. 8-1A, a “del (E746-A750) mutation” in which the nucleotide sequence from 2235th to 2249th (start codon A is the first, the same applies hereinafter) deleted (the gene Along with the deletion mutation, a mutant protein in which the alanine from the 746th glutamic acid to the 750th is deleted when the starting methionine is the first is generated), from 2240th to 2251st as shown in FIG.
- a “del (E746-A750) mutation” in which the nucleotide sequence from 2235th to 2249th (start codon A is the first, the same applies hereinafter) deleted (the gene Along with the deletion mutation, a mutant protein in which the alanine from the 746th gluta
- A750P (G) mutation (with the deletion / insertion mutation of the gene, The glutamic acid from syn to 749th is deleted, resulting in a mutant protein in which the 750th alanine is replaced with proline), and the base corresponding to the start codon A to 2238 as shown in FIG. 11-1A,
- the third base of the codon encoding E746 (GAG) is not "G” (Pao et al., 2005, PloS Medicine, Vol. 2, Issue 3: e73) but “A” (Paez et al., 2004, Science, vol. 304, 1497-1500) and “del (L747-E749) -A750P (A) mutation”.
- point mutations are also included.
- the transcript of the del (E746-A750) mutant gene has two discontinuous junctions and only one base (in the case of L747-E749) -A750P (A)) or two bases (L747- E749) -A750P (G)).
- the bases on the 5 ′ side and the 3 ′ side adjacent to the discontinuous junction located formally on the 3 ′ side are used as the first and second reference bases, respectively.
- the number of bases from the base corresponding to the second reference base to the 3 ′ end was shifted one by one to set the 3 ′ end base of the RNAi sense strand region (3 ′ end base setting step).
- a base sequence containing 19 consecutive bases including the first and second reference bases of the transcript was set as an RNAi sense strand region (RNAi sense strand region setting step).
- a base sequence containing a base sequence complementary to the base sequence of the set RNAi sense strand region was defined as an RNAi antisense strand region (RNAi antisense strand region setting step).
- Table 1 shows the del (E746-A750) mutant gene
- Table 2 shows the del (L747-T751) -L747S mutant gene
- Table 3 shows the del (L747-E749) -A750P (G) mutation.
- Table 4 shows the nucleotide sequences of the sense strand region (ss) and antisense strand region (as) of siRNA designed for the del (L747-E749) -A750P (A) mutant gene, respectively.
- the base sequences shown in each table exclude the 3 'terminal added base consisting of UU at the 3' end of the sense strand region and the antisense strand region.
- corresponds to the number of a sequence table.
- RNAi sense strand region is an siRNA consisting of 19 bases. That is, in “si746 / 50” of “si746 / 50-3D19”, “si” is siRNA, “746/50” is del (E746-A750) mutation 746 to 750, and “3D19” “D” is a deletion mutation, “3” is 3 bases from the second reference base to the 3 ′ end, and “19” is 19 bases in the RNAi sense strand region.
- siRNA name for the del (L747-E749) -A750P (A) mutant gene shown in Table 4 is distinguished from the siRNA for the del (L747-E749) -A750P (G) mutant gene shown in Table 3.
- “del (L747-E749) -A750P (G) mutation is added to“ si747 / 49-3D19 ”by adding“ (A) ”like“ si747 / 49 (A) -3D19 ”. Differentiated from siRNA for genes.
- ⁇ in the sense strand region (ss) in each table indicates a discontinuous junction
- ⁇ in the antisense strand region (as) corresponds to a discontinuous junction in the sense strand region. Indicates the position to perform.
- the underlined base indicates the second reference base.
- the inserted base (2 bases) in the del (L747-E749) -A750P (G) mutation is shown in bold.
- each siRNA was outsourced to Sigma-Aldrich.
- the synthesized siRNA was subjected to annealing treatment of the sense strand region and the antisense strand region, which was directly used for the experiment.
- reporter gene expression plasmid For selection of evaluation of RNAi effect of EGFR-siRNA prepared in (1) above, pGL3-TK (Ohnishi Y., et al.) Expressing the firefly luciferase gene al., 2006, Journal of RNAi and Gene Silencing, Vol. 2: 154-160) and the phRL-TK plasmid (Promega) expressing Renilla luciferase gene to target siRNA Construction of reporter gene expression plasmids of dominant mutant gene and non-targeted wild type gene was performed.
- the design of the synthetic oligo DNA including the mutation site, insertion into the reporter gene expression plasmid, and selection method were in accordance with Ohnishi Y., et al., 2008, PloS One, Vol. 3, Issue 5: e2248. Specifically, deletion or deletion of each gene of del (E746-A750), del (L747-T751) -L747S, or del (L747-E749) -A750P in the pathogenesis of non-small cell lung cancer Oligo DNA sense strand regions and antisense strand regions each containing an insertion mutation site were synthesized (consigned to Sigma-Aldrich).
- the linker sequence is underlined, the discontinuous junction in the EGFR gene is “ ⁇ ”, the second reference base in the sense strand region (ss) of each table is black and white inverted characters, and in Table 5, del (L747 The insertion base (2 bases) in the -E749) -A750P (G) mutant gene and the insertion base (1 base) in the del (L747-E749) -A750P (A) mutant gene are shown in bold in Table 6.
- EGFR (T790T) and EGFR (T790M) are synthetic oligo DNAs for point mutation of EGFR, and a base expressed in lower case indicates a point mutation site.
- annealing treatment of each synthesized strand oligo DNA was performed. Specifically, single strand oligo DNA (final concentration: 1 ⁇ M each), 10 ⁇ annealing buffer (Invitrogen, final concentration: 1 ⁇ ) and a sense strand region and an antisense strand region so that the final volume is 10 ⁇ L Sterile water was mixed, heat-treated at 80 ° C. for 5 minutes, and then allowed to stand at room temperature for 30 minutes to form double strands.
- the double-stranded oligo DNA was inserted into the two kinds of plasmids treated with restriction enzymes.
- the normal allele is the pGL3-TK plasmid
- the dominant mutant gene is the reporter gene in the phRL-TK plasmid.
- the wild type EGFR reporter gene expression plasmid and the dominant mutant EGFR reporter gene expression plasmid were constructed by inserting into the 3 ′ untranslated region (3′UTR).
- reporter gene expression plasmids in which the reporter gene was replaced with normal and dominant mutant genes were constructed in the same manner.
- HeLa cells were dispersed by trypsin digestion, adjusted to a cell density of 1 ⁇ 10 5 cells / cm 2 and seeded in a 96-well culture plate, and the HeLa cells contained no antibiotics. Culturing was performed with the DMEM culture medium.
- plasmids After 24 hours, three types of plasmids were used: (a) pGL3-TK backbone plasmid (60 ng / well) which is a wild type EGFR reporter gene expression plasmid, (b) phRL which is a reporter gene expression plasmid of each mutant EGFR gene -TK backbone plasmid (20 ng / well) and (c) pSV- ⁇ -galactosidase control plasmid (Promega) (10 ng / well) which is a ⁇ -galactosidase gene expression plasmid not subject to RNAi expression suppression as an exogenous control
- pG-siRNAs final concentration 20 nM
- siRNA that does not induce RNAi at a final concentration of 20 nM (siControl; QIAGEN) was used.
- Lipofectamine 2000 (Invitrogen) was used for introduction of these nucleic acids. The transfection method followed the attached protocol. 24 hours after introduction of the nucleic acid, prepare a cell extract using the (Dual-Luciferase reporter assay system) cell lysis buffer attached to the Dual-Luciferase reporter assay system (Promega) kit.
- each of the expressed reporter genes (and two luciferases) and the control ⁇ -galactosidase was measured using a Dual-Luciferase reporter assay system (Promega) and a Beta-Glo assay system (Promega), respectively. Fusion Universal Microplate Analyzer (Perkin Elmer) was used for the measurement. Furthermore, regarding the reporter, in order to eliminate the possibility of measurement differences due to differences in the activity of the two luciferases used, each mutant gene del (E746-A750), del (L747-T751) -L747S, del (L747-E749) -An experiment was also conducted in which the reporter gene was replaced with the A750P gene.
- FIG. 8-1B shows the results of each EGFR-siRNA against the del (E746-A750) mutant gene
- FIG. 9-1B shows the results of each EGFR-siRNA against the del (L747-T751) -L747S mutant gene.
- the results of each EGFR-siRNA against the del (L747-E749) -A750P (G) and del (L747-E749) -A750P (A) mutant genes are shown in FIGS. 10-1B and 11-1B, respectively.
- the luciferase activities of the non-target wild-type EGFR gene and the target mutant EGFR gene were calculated as relative values when the luciferase activity of each siControl was 1.0.
- the luciferase activity of each sample is corrected by the expression level of ⁇ -galactosidase, which is an exogenous control that is not subject to expression suppression by RNAi.
- the base length of the entire RNAi sense strand region is maintained at 19 bases by introducing the 3 ′ end base of the RNAi sense strand region one by one from the second reference base toward the downstream side, the base length of the entire RNAi sense strand region is maintained as shown in FIG. As shown in FIG. -1B and FIG. 9-1B, when the 4th to 15th bases are set as the 3 ′ terminal bases of the RNAi sense strand region (indicated by ⁇ 4D19 to ⁇ 15D19), the expression of the control (siControl) It was revealed that the expression of the mutant EGFR gene was strongly suppressed as compared with the control, but the expression of the wild-type EGFR gene was not significantly suppressed or almost the same as the control. That is, this means that it is a useful siRNA with a high ASP-RNAi effect.
- FIG. 10-1B when the 2nd to 9th bases are set to the 3 ′ terminal base of the RNAi sense strand region, the expression of the mutant EGFR gene is strongly suppressed compared to the control (siControl) expression.
- the expression of the wild-type EGFR gene was not significantly suppressed or hardly changed from the control.
- This result is slightly different from the result of the del (E746-A750) mutation or the del (L747-T751) -L747S mutation.
- FIGS. 10-1A and 11-1A there are two discontinuous junctions in del (L747-E749) -A750P (G), (A), and 2 bases and 1 base respectively.
- -9D19 and si747 / 49 (A) -3D19 to -11D19 were prepared, with the 5 ′ and 3 ′ bases adjacent to the 5 ′ discontinuous junction being the first and second reference, respectively.
- si747 / 49-4D19 to -11D19 and si747 / 49 (A) -4D19 to -12D19, del (E746-A750) mutation or del (L747-T751) -L747S Consistent with mutation results.
- an RNAi molecule that targets a transcript containing a discontinuous junction can be arbitrarily sequenced as long as it contains two bases (first and second reference bases) sandwiching the discontinuous junction. It is not necessarily set, and it has been shown that the desired ASP-RNAi effect cannot be obtained unless the first and second reference bases are located at predetermined positions in the RNAi sense strand region. Although this tendency is somewhat fluctuated, as shown in Example 5 and FIGS. 12 and 13 to be described later, this phenomenon is recognized regardless of the difference in the base sequence of the target region in the same gene or the difference in the target gene. It became clear that.
- Example 2 EGFR-siRNA deletion (or deletion / insertion) mutant gene-specific RNAi effect on human non-small cell lung cancer-derived cell lines>
- siRNA whether or not they show a specific expression suppression effect (ASP-RNAi effect) also against endogenous mutant EGFR was examined.
- PC3 cells derived from human lung cancer having EGFR del (L747-E749) -A750P were used as an example.
- the EGFR-siRNA was endogenous using si747 / 49-3D19 and si747 / 49 (A) -8D19, which had a particularly suppressive effect on the del (L747-E749) -A750P mutation in Example 1. Mutant EGFR RNAi knockdown was performed.
- the three groups of cells were cultured in a 6-well culture plate using the culture solution of (1), and collected after 24 hours.
- PCR temperature and time conditions include initial denaturation (95 ° C, 10 minutes), denaturation (94 ° C, 30 seconds), annealing (55 ° C, 30 seconds), and extension reaction (72 ° C, 30 seconds). The condition was repeated 26 times. Thereafter, the PCR amplification product was analyzed by electrophoresis (7% polyacrylamide gel, 100 mA, 1 hour). The primer sequences used are shown in Table 7.
- Example 3 Evaluation of effects of EGFR-siRNA on cell death and cell proliferation ability on human non-small cell lung cancer-derived cell lines> Specific and effect of endogenous mutant EGFR (del (L747-E749) -A750P) using EGFR-siRNA (si747 / 49-3D19 and si747 / 49 (A) -8D19) shown in Example 2 Whether or not the expression suppression can affect cell proliferation and cell death was examined with respect to the total cell number, cytotoxicity, cell proliferation / survival activity, and cell death (apoptosis).
- Cell culture (cell density: about 3 ⁇ 10 4 cells / well) was performed in a 96-well culture plate using the culture solution of (1) above, and subjected to each evaluation experiment after 1 day and 4 days.
- si747 / 49-3D19 was subjected to the same evaluation experiment after 2 days and 6 days together with the control.
- FIG. 16 shows the result. This figure shows the relative value (%) of the LDH amount when the LDH amount of “no siRNA” on the first day, which is regarded as the total number of cells, is defined as 100%.
- EGFR-siRNA significantly reduced its total number of PC3 cells both “no siRNA” and “siControl”. That is, this result means that si747 / 49-3D19 suppressed the cell proliferation of PC3 cells.
- si747 / 49-3D19 is specific and effective against PC3 endogenous dominant mutant EGFR gene (del (L747-E749) -A750P), which promotes cell proliferation activity through constitutive activation. It shows that expression was suppressed.
- Cytotoxicity evaluation In order to evaluate cytotoxicity in PC3 cells after introduction of si747 / 49-3D19, the amount of LDH released extracellularly due to cytotoxicity and present in the culture solution was determined using CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega). It was measured. The experimental operation was performed according to the attached protocol, and the absorbance was measured using BenchMark Plus (BIO-RAD). The negative controls used were the same two controls (no siRNA and siControl) used when measuring the cell proliferation ability.
- FIG. 17 shows the result.
- the relative value (%) when the LDH amount (sample added with a cell lysis buffer as in the cell proliferation ability evaluation experiment) contained in all cells on the first day of “no siRNA” is 100%.
- si747 / 49-3D19 does not induce cytotoxicity or cell death due to suppression of endogenous mutant EGFR expression equivalent to or higher than “no siRNA” or “siControl”.
- Cell proliferation and survival activity evaluation (1) [Method] In order to evaluate cell proliferation and survival activity in PC3 cells after si747 / 49-3D19 introduction, CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega) was used, and NADH (nicotinamide adenine dinucleotide; MTS reduction action by nicotinamide adenine dinucleotide) was measured. The experimental operation was performed according to the attached protocol, and the absorbance was measured using BenchMark Plus (BIO-RAD). The negative controls used were the same two controls (no siRNA and siControl) used when measuring the cell proliferation ability.
- Cell proliferation and survival activity evaluation (2) [Method] In order to evaluate cell proliferation and survival activity in PC3 cells after si747 / 49-3D19 introduction, the relative amount of ATP in the cells was measured using CellTiter-Glo Assay (Promega). The experimental procedure was performed according to the attached protocol, and the luminescence level was measured using Fusion Universal Microplate Analyzer (Perkin Elmer). The negative controls used were the same two controls (no siRNA and siControl) used when measuring the cell proliferation ability.
- cell proliferation and survival activity show the relative values on the first day and the fourth day when the relative ATP amount on the first day of culture without “siRNA” is 100%.
- si747 / 49-3D19 significantly suppressed the growth rate or decreased the survival rate for both “no siRNA” and “siControl” on the 4th day of culture. .
- the results are shown in FIG.
- the caspase 3/7 activity indicates a relative value on the first day and the fourth day when the activity on the first day of culture without “siRNA” is defined as 100%.
- si747 / 49-3D19 did not show a significant change in caspase 3/7 activity when compared with either “no siRNA” or “siControl” on the 4th day of culture. This indicates that suppression of mutant EGFR-specific expression by si747 / 49-3D19 does not induce apoptosis.
- Example 4 Point mutation gene-specific RNAi effect of EGFR-siRNA on human non-small cell lung cancer-derived cell line> (1) Examination of ASP-RNAi effect of EGFR-siRNA on EGFR gene [Method] As described in Example 1, in non-small cell lung cancer patients, point mutations are also known as gain-of-function mutations associated with disease in the EGFR gene (Paez GJ et al., Science, 2004, 304). ; 1497-1500). For example, as shown in FIG.
- T790M mutation in which the 2369th base C is substituted with T (a point mutation in which the 790th tryptophan is amino acid changed to methionine (T790M) following the point mutation of the gene).
- T790M methionine
- Embodiment 1 If there is an expression vector operably linked to other siRNA having a different structure from the inhibitor and / or DNA encoding the siRNA, it should be used in combination with the EGFR-siRNA described in Example 1 above. Therefore, a higher suppression effect is expected.
- siRNA that specifically suppresses the expression of the point mutation type EGFR (epidermal growth factor receptor) gene was designed, and the expression suppression effect on the mutant gene (cancer causing gene) was verified.
- Table 8 shows the base sequences of the sense strand region (ss) and the antisense strand region (as) of siRNA designed for the T790M mutation. In the base sequence, the base shown in bold letters corresponds to the point mutation site. In the base sequences shown in each table, the 3 ′ terminal added base consisting of UU at the 3 ′ end of the sense strand and the antisense strand is excluded for convenience of description. Moreover, the sequence number in a table
- EGFR-siRNA name in each table for example, “si790-9C / U18” in Table 8 has 9 bases from the point mutation site of T790M mutation to the 5 ′ terminal base of the sense strand region. It indicates that the base C on the wild-type EGFR gene has been replaced with U (T) by point mutation, and that the number of bases in the sense strand region and the antisense strand region are both 18 bases. .
- reporter gene expression plasmid and reporter assay For selection of evaluation of RNAi effect of EGFR-siRNA prepared in 1 above, reporter gene expression of dominant mutant gene targeted by siRNA and non-target wild type gene Plasmid construction, cell culture, transfection and reporter assays were performed. The basic operation procedure was in accordance with the method described in Example 1.
- si790-9C / U18 was not a preferred siRNA because it has a relatively strong suppression effect on wild-type EGFR gene expression compared to siControl, but si790-10C / U18 It was revealed that si790-11C / U18 has almost no expression suppressing effect on the wild-type EGFR gene, while it has an effective suppressing action on the mutant EGFR gene.
- si790-10C / U18 and si790-11C / U18 were shown to be suitable EGFR-siRNAs.
- Example 5 Transient mutation gene-specific RNAi effect of BCR-ABL-siRNA on BCR-ABL chimeric gene>
- the siRNA (BCR-ABL-siRNA) having the constitution of the present embodiment 1 targeting the BCR-ABL chimeric gene generated by the translocation mutation in the Philadelphia chromosome is designed, and the BCR-ABL chimeric gene, which is a leukemia causative gene, is designed. The expression suppression effect was verified.
- the BCR-ABL chimeric gene is considered as a causative gene for CML and ALL found in patients with the Philadelphia chromosome, and the BCR-ABL-siRNA of the present invention is a hyperfunctional BCR-ABL gene. If only the expression of can be specifically suppressed, it can be an effective prophylactic or therapeutic agent for CML and ALL in patients with the Philadelphia chromosome.
- BCR-ABL chimeric genes It is known that the breakpoints of the BCR gene in the Ph translocation are concentrated at two locations, Major-BCR (downstream: M-BCR) and minor-BCR (upstream: m-BCR). In neutrophil leukemia / essential thrombocythemia, further downstream ⁇ -BCR (p230) involvement has been reported.
- P210BCR / ABL M-BCR breakpoint
- p190BCR / ABL m-BCR breakpoint
- p230BCR / ABL ⁇ -BCR breakpoint
- BCR-ABL-siRNA was designed and designed according to the RNAi molecule design method described in Embodiment 1 for the BCR-ABL chimeric gene having M-BCR as the breakpoint most frequently found in the disease. It was prepared and verified whether or not the expression of these translocation mutant genes could be specifically suppressed.
- BCR-ABL-siRNA For the BCR-ABL chimeric gene with M-BCR as the breakpoint, the wild-type ABL gene and the wild-type BCL gene are expressed on the mutant gene product (mutant mRNA).
- BCR-ABL-siRNA was designed and prepared in the same manner as in Example 1, using the 5 ′ and 3 ′ bases adjacent to this discontinuous junction as the first and second reference bases, respectively.
- Table 9 shows specific base sequences of BCR-ABL-siRNA designed and used in this example.
- Table 9 shows the base sequences of the sense strand region (ss) and the antisense strand region (as) of siRNA designed for the BCR-ABL chimeric gene having M-BCR as a breakpoint.
- the base sequences shown in each table exclude the 3 ′ terminal added base consisting of UU at the 3 ′ end of the sense strand region and the antisense strand region for convenience of description.
- corresponds to the number of a sequence table.
- each siRNA was outsourced to Sigma-Aldrich.
- the synthesized siRNA was subjected to annealing treatment of the sense strand region and the antisense strand region, which was directly used for the experiment.
- reporter gene expression plasmid For construction of reporter gene expression plasmid, design of synthetic oligo DNA containing mutation site, insertion into reporter gene expression plasmid, and selection method, refer to “(3) Reporter gene expression in Example 1. According to the method described in “Construction of Plasmid”. Table 10 shows the specific base sequence of the synthetic oligo DNA used.
- each BCR-ABL-siRNA against the BCR-ABL chimeric gene results of each BCR-ABL-siRNA against the BCR-ABL chimeric gene are shown in FIGS. 12-1B and 13-1B.
- the target gene-specific expression suppression effect of each BCR-ABL-siRNA was shown to be BCR-ABL chimeric gene and wild type ABL gene (FIG. 12-1B), and BCR-ABL chimeric gene and wild type BCR gene (FIG. 13-1B). ).
- the luciferase activity of the non-target wild-type ABL or BCR gene and the target BCR-ABL chimeric gene was calculated as a relative value when the luciferase activity of each siControl was 1.0. .
- the luciferase activity of each sample is corrected by the expression level of ⁇ -galactosidase, which is an exogenous control that is not subject to expression suppression by RNAi.
- FIG. 13-1B When the base length of the entire RNAi sense strand region is maintained at 19 bases by introducing the 3 ′ base of the siRNA sense strand region by shifting one by one starting from the second reference base toward the downstream side, FIG. As shown in -1B and FIG. 13-1B, when the 4th to 13th bases are set to the 3 ′ terminal base of the RNAi sense strand region (indicated by ⁇ 4D19 to ⁇ 13D19), the expression of the control (siControl) As compared with, the expression of the BCR-ABL chimeric gene was strongly suppressed, but the expression of the wild-type ABL or BCR gene was not significantly suppressed or almost the same as the control. That is, this shows that it is a useful siRNA with a high ASP-RNAi effect.
- Example 6 Influence on cell survival activity of EGFR-siRNA and anticancer drug gefitinib against human non-small cell lung cancer-derived cell line>
- del L747-E749
- PC3 and PC9 cells which are human non-small cell lung cancer cell lines having del (L747-E749) -A750P mutation and del (E746-A750) mutation of EGFR, and control We used human HeLa cells with wild-type EGFR.
- PC3 cells were cultured in the same manner as in the above “Example 2: (1)”, and HeLa cells were cultured in the same manner as in the above “Example 1: (4)”.
- PC9 cells were cultured at 37 ° C. under 5% CO 2 using RPMI-1640 culture medium (Wako) containing 10% fetal bovine serum (FBS; Invitrogen).
- EGFR-siRNA introduction of EGFR-siRNA into PC3 cells by electroporation
- the EGFR-siRNA was introduced into cells in the same manner as in “Example 2: (2)”. Specifically, PC3 cells cultured in the culture medium of (1) above were dispersed by trypsin digestion, and then collected by centrifugation (120 G, 5 minutes), and about 1 ⁇ 10 6 cells were obtained at a final concentration of 100. , 50, 25, 10, 5, 1 and 0 nM EGFR-siRNA (si747 / 49-3D19) or 100 ⁇ L of electroporation buffer (Amaxa Cell Line Nucleofector Solution V containing siRNA that does not induce RNAi (siControl; QIAGEN)) And Amaxa).
- Electroporation (program: U-005, gene transfer system Nucleofector, Amaxa) was performed according to the attached protocol, and the siRNA was introduced into the cells. The cells were cultured in the medium described in “Example 2: (1)”, and the cell viability was measured after 3 days.
- EGFR-siRNA introduction of EGFR-siRNA into PC9 cells by lipofection method
- Cell culture cell density: about 1 ⁇ 10 5 cells / cm 2
- EGFR-siRNA si746 / 50-4D19
- a final concentration of 100, 50, 25, 10, 5, 1 and 0 nM and siRNA that does not induce RNAi were used with PC9 using Lipofectamine 2000 (Invitrogen) Introduced into cells.
- the transfection method followed the attached protocol. Cell viability was measured after 3 days of culture.
- FIGS. 23A and 23B show the results of PC9 cells having the del (E746-A750) mutation
- FIG. 23C shows the results of HeLa cells. Each figure shows a relative value when the cell survival activity in an untreated cell is 100%.
- PC9 cells showed significant cell growth inhibition and decreased survival activity at gefitinib concentrations of 10 -2 ⁇ M or higher, whereas PC3 cells and HeLa cells both had concentration-dependent cell growth suppression and survival at 1 ⁇ M or higher. The activity decreased.
- PC9 cells are gefitinib-sensitive cells that can suppress their proliferation even when administered with a small amount of gefitinib, whereas PC3 cells are also affected by HeLa cells, that is, even cells with wild-type EGFR are suppressed. It was suggested that the cells are gefitinib-resistant cells that do not exhibit the effect of suppressing their cell proliferation and survival activity unless such high concentrations of gefitinib are administered.
- gefitinib can be an effective anticancer agent for non-small cell lung cancer with gefitinib-sensitive EGFR mutation such as del (E746-A750) mutation, but has del (L747-E749) -A750P mutation.
- non-small cell lung cancer that has acquired resistance to gefitinib has been shown to have no effect unless administered with a high concentration of gefitinib that can cause harmful side effects to the individual.
- FIG. 24A shows EGFR-siRNA (si747 / 49-3D19) against PC3 cells having the del (L747-E749) -A750P mutation
- FIG. 24B shows PC9 cell EGFR-siRNA (si746 / D750) having the del (E746-A750) mutation
- FIG. 24C shows the results of EGFR-siRNA (si747 / 49-3D19) against HeLa cells. Each figure shows a relative value when the cell survival activity in an untreated cell is 100%.
- EGFR-siRNA (si746 / 50-4D19 and si747 / 49-3D19) markedly suppresses cell proliferation and decreases survival activity against both PC3 and PC9 cells with mutations in EGFR.
- EGFR-siRNAs showed an inhibitory effect on cell proliferation and survival activity against HeLa cells having wild-type EGFR.
- the EGFR-siRNA of the present invention has little effect on the expression of wild-type EGFR (that is, there is no side effect or it is infinitely small), and gefitinib resistant or sensitive EGFR It was proved that even mutations can induce highly specific cell growth suppression and reduced survival activity at lower concentrations than gefitinib.
- Example 7 Production of a model mouse by heterogeneous transplantation of human non-small cell lung cancer-derived cell lines and the effect of EGFR-siRNA on it> The effect of EGFR-siRNA verified at the cell level was verified at the individual level.
- PC3 cells were transplanted subcutaneously into nude mice, a mouse subcutaneous tumor model was created, and the tumor growth inhibitory effect of EGFR-siRNA administration was verified using the model mouse.
- Tumor volume was calculated from the tumor diameter one week after transplantation of PC3 cells (6 weeks of age), and for the tumor reaching about 50 mm 3 , the three prepared above Samples, ie, siRNA-free atelocollagen solution, siControl and 20 ⁇ g / 200 ⁇ L solution of EGFR-siRNA, were each administered directly to the tumor at 1.0 mg / kg body weight. Tumor volume was calculated using the following formula:
- FIG. 26 The time course of tumor volume by administration of EGFR-siRNA is shown in FIG. 26 (si747 / 49-3D19 administration) and FIG. 29 (si747 / 49 (A) -8D19 administration), and the wet weight of the excised tumor is shown in FIG. 27 (si747 / 49-3D19 administration) and FIG. 30 (si747 / 49 (A) -8D19 administration), respectively.
- the population administered with EGFR-siRNA (si747 / 49-3D19 or si747 / 49 (A) -8D19) significantly suppressed the enlargement of subcutaneous tumors compared to the individual administered with atelocollagen solution alone and siControl Was shown to be. Furthermore, the wet weight of the tumor was also significantly reduced compared to them.
- the EGFR-siRNA of the present invention is effective in suppressing cancer cell proliferation not only at the cellular level but also at the individual level.
- the EGFR-siRNA of the present invention has great side effects in the administration of gefitinib, and suppresses the proliferation and survival activity of cancer cells extremely effectively and safely against the EGFR mutation resistant to gefitinib that could not be used so far It was proven that
- a cancer cell of a non-small cell lung cancer patient has a mutated EGFR gene can be examined by a highly sensitive detection method such as LNA-PNA-PCR clamp method (Patent No. 4216266). If the patient's EGFR gene has a gefitinib-sensitive mutation such as the del (E746-A750) mutation, gefitinib can be a very effective therapeutic agent. However, in the case of cancer cells that have acquired gefitinib resistance even though they have mutations such as del (L747-E749) -A750P, no effective and side-effect drug has been known to date.
- the EGFR-siRNA of the present invention can be a very effective anticancer agent even for non-small cell lung cancer patients having gefitinib-resistant EGFR gene mutation for which such an effective treatment method has not been established. It was done.
- Example 8 Verification of side effects due to suppression of endogenous wild-type EGFR gene expression>
- the EGFR-siRNA of the present invention specifically suppresses only the mutant EGFR gene, whereas the conventional siRNA distinguishes between the wild-type and mutant EGFR genes. Both strongly suppress expression. Then, it verified about the presence or absence of the side effect at the time of administering EGFR-siRNA of this invention and the conventional siRNA to a mouse
- siRNAs were administered intraperitoneally to ICR mice (male, 10 weeks old).
- the experimental group consists of only atelocollagen solution without siRNA administration (no siRNA), siRNA that does not induce RNAi (siControl; QIAGEN), si747 / 49-3D19 that specifically suppresses expression of mutant EGFR gene, and mouse
- siEgfr that suppresses the expression of endogenous wild-type EGFR gene expressed in vivo. These were prepared in the same manner as in Example 7 and administered intraperitoneally to mice.
- specific base sequences of siEgfr designed and used in this example are shown in Table 11.
- FIG. 31 shows the result. Endogenous wild-type EGFR gene is expressed in total bilirubin (A), direct bilirubin (B), indirect bilirubin (C), and alkaline phosphatase (D) in plasma compared to no siRNA group and siControl group A significant increase was observed in the suppressive siEgfr administration group. On the other hand, no significant change was observed in the EGFR-siRNA (si747 / 49-3D19) administration group of the present invention. This significant increase in blood parameters was attributed to the suppression of endogenous wild-type EGFR expression by administration of siEgfr, suggesting that hepatobiliary disorders were induced from the blood parameter data changed. It was done.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
ASPスコア=[(対照RNAi分子で処理した正常型遺伝子の標準化した発現量に対する前記RNAi分子で処理した正常型遺伝子の標準化した発現量の相対比)-(対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)]×(1-対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)
(式中、対照RNAi分子は、前記正常型遺伝子及び変異遺伝子の発現に影響を及ぼさないRNAi分子である)
前記RNAi分子が標的である優性変異遺伝子の転写産物上に生じる少なくとも一つの不連続接合点、及び該転写産物の連続する16~30塩基の配列に一致する塩基配列を含むRNAiセンス鎖領域、並びにそれに相補的な塩基配列を含むRNAiアンチセンス鎖領域を含み、かつ前記RNAiセンス鎖領域上のいずれか一の不連続接合点に隣接する3’側の塩基から下流側に向かって4~15番目のいずれか一の塩基が該RNAiセンス鎖領域の3’末端塩基を構成する、前記遺伝子発現抑制剤。
ASPスコア=[(対照RNAi分子で処理した正常型遺伝子の標準化した発現量に対する前記RNAi分子で処理した正常型遺伝子の標準化した発現量の相対比)-(対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)]×(1-対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)
(式中、対照RNAi分子は、前記正常型遺伝子及び変異遺伝子の発現に影響を及ぼさないRNAi分子である)
前記RNAi分子が標的である優性変異遺伝子の転写産物上に生じる少なくとも一つの不連続接合点、及び該転写産物の連続する16~30塩基の配列に一致する塩基配列を含むRNAiセンス鎖領域、並びにそれに相補的な塩基配列を含むRNAiアンチセンス鎖領域を含み、かつ前記RNAiセンス鎖領域上のいずれか一の不連続接合点に隣接する3’側の塩基から下流側に向かって4~15番目のいずれか一の塩基が該RNAiセンス鎖領域の3’末端塩基を構成する、前記遺伝子発現抑制剤。
を含む、前記設計方法。
ASPスコアは、以下の式から算出される、前記設計方法。
(式中、対照RNAi分子は、前記正常型遺伝子及び変異遺伝子の発現に影響を及ぼさないRNAi分子である)
(23)RNAiセンス鎖領域及びRNAiアンチセンス鎖領域の3’末端にさらにTT又はUUを付加する、(21)又は(22)に記載の設計方法。
1-1.概要
本発明の第1の実施形態は、優性変異遺伝子発現抑制剤である。本発明の抑制剤は、RNAi分子及び/又はそれをコードする発現ベクターを有効成分として含み、優性変異遺伝子の発現を選択的に抑制することを特徴とする。
本明細書において、「RNAi分子」とは、生体内においてRNA干渉(RNA interference)を誘導し、標的とする優性変異遺伝子の転写産物の分解を介してその遺伝子の発現を転写後翻訳前に抑制(サイレンシング)することができる分子をいう。RNAi機構を介して遺伝子の発現を抑制できる分子であれば、一本鎖分子又は二本鎖分子のいずれであってもよい。例えば、siRNA(small interfering RNA)のような二本鎖分子、shRNA(short hairpin RNA)又はmiRNA(micro RNA)のような一本鎖分子が挙げられる。RNA干渉については、例えば、Bass B.L., 2000, Cell, 101, 235-238;Sharp P.A., 2001, Genes Dev., 15 ,485-490;Zamore P.D., 2002, Science, 296, 1265-1269;Dernburg ,A.F. & Karpen, G.H., 2002, Cell, 111,159-162を参照されたい。なお、本明細書では、RNAi機構を介した転写後の遺伝子サイレンシングを、以下、「遺伝子の発現抑制」として表す。
本実施形態の抑制剤に含まれるRNAi分子は、標的である優性変異遺伝子の転写産物上に生じる少なくとも一つの不連続接合点を含むRNAiセンス鎖領域、及びそれに相補的な塩基配列を含むRNAiアンチセンス鎖領域を含む。
本実施形態の抑制剤に含まれるRNAi分子は、いずれの形態の場合にも、RNAiセンス鎖領域(0601)、RNAiアンチセンス鎖領域(0602)及び不連続接合点(0603)を必須の構成要素として含む。以下、RNAi分子に共通する構成要素について説明をする。
式中、対照RNAi分子は、本実施形態の有効成分であるsiRNA分子のネガティブコントロールとなるRNAi分子で、前記正常型遺伝子及び変異遺伝子の発現に影響を及ぼさないRNAi分子であり、それ故、上記式では、対照RNAi分子で処理した標準化した遺伝子の発現量を100%とみなす。例えば、標的となる遺伝子が存在しない任意の塩基配列を含むRNAi分子が該当する。上記式において、標準化後の発現量の相対比が「1.0」を超えた場合、それは発現抑制効果が無いものとみなし、その相対比を「1.0」として算出する。
本実施形態の抑制剤に含まれるRNAi分子がsiRNAのような二本鎖分子の場合、前記図6Aに示すように、上記RNAi分子共通構成要素であるRNAiセンス鎖領域(0601)、RNAiアンチセンス鎖領域(0602)及び不連続接合点(0603)に加えて、任意でさらにそれぞれのポリペプチド鎖の3’末端に3’末端付加塩基(0606)を含むことができる。「3’末端付加塩基」(0606)は、TT(チミン‐チミン)又はUU(ウラシル‐ウラシル)の2塩基で構成される。この塩基を付加したRNAi分子は、RNAi抑制効率を高めることができる(Tuschl T et al., 1999, Genes Dev, 13(24):3191-7)。
本実施形態の抑制剤に含まれるRNAi分子がshRNAのような一本鎖分子の場合、前記図6Bに示すように、上記RNAi分子共通構成要素であるRNAiセンス鎖領域(0601)、RNAiアンチセンス鎖領域(0602)及び不連続接合点(0603)に加えて、さらにRNAiセンス鎖領域(0601)と、それとは逆向きのRNAiアンチセンス鎖領域(0602)とを連結する短いスペーサー配列(0608)を含む。スペーサー配列は、通常3~24塩基、好ましくは、4~15塩基からなる任意の塩基配列とすることができる。したがって、RNAi分子が一本鎖の場合、分子全体として、35塩基(16×2+3)~84塩基(30×2+24)からなる。RNAi分子内では、RNAiセンス鎖領域とRNAiアンチセンス鎖領域が互いに塩基対合し、その間に位置するスペーサー配列がループ構造を形成することによって、分子全体がヘアピン型のステム-ループ構造をなし得る。前記構造を有する一本鎖RNAi分子が細胞内に導入されると、細胞質内でDicerと呼ばれるエンドヌクレアーゼの働きによって二本鎖siRNAに加工され、そのうちRNAiアンチセンス鎖領域がRISC(RNA-induced silencing complex)複合体に取り込まれた後、前述の二本鎖RNAi分子と同様のRNAi機構によって標的遺伝子の転写後翻訳前発現を抑制することができる。一本鎖分子におけるRNAiセンス鎖領域(0601)とRNAiアンチセンス鎖領域(0602)は、前記二本鎖RNAi分子と同様に、それぞれの領域の3’末端に3’末端付加塩基を含むこともできる。一本鎖分子における5’末端、及び/又は3’末端には、任意の配列を付加することもできる。例えば、5’末端及び/又は3’末端にステムループ構造を形成し得る塩基配列を付加することもできる。
本明細書において「発現ベクター」とは、本実施形態の阻害剤に含まれる有効成分であって、前記RNAi分子をコードするDNAを発現可能なように発現用ベクター内に挿入したベクターである。
本実施形態の抑制剤に含まれるRNAi分子の設計方法について説明をする。本設計方法は、図7で示すように、基準塩基設定工程(0701)、3’末端塩基設定工程(0702)、RNAiセンス鎖領域設定工程(0703)、及びRNAiアンチセンス鎖領域設定工程(0704)を含む。以下、それぞれの工程について説明をする。
本実施形態の抑制剤に含まれる発現ベクターの調製方法は、基本的には、当該分野で公知の方法、例えば、Sambrook, J. et. al., (1989) Molecular Cloning: a Laboratory Manual Second Ed., Cold SpringHarbor Laboratory Press, Cold Spring Harbor, New Yorkに記載の方法に従って調製することができる。
本実施形態の優性変異遺伝子発現抑制剤の一例として、変異型EGFR(上皮成長因子受容体)遺伝子の発現を特異的に抑制するRNAi分子(EGFR-RNAi分子)を有効成分とする変異型EGFR遺伝子発現抑制剤が挙げられる。ここでいう変異型EGFR遺伝子とは、後天的に発生する優性変異遺伝子で、非小細胞肺癌(non-small cell lung cancer;NSCLC)の原因となる遺伝子である。EGFRの細胞外ドメインに上皮成長因子(EGF)等のリガンドが結合すると、通常は細胞内ドメインのチロシンキナーゼ活性化され、自己リン酸化作用が作動する。変異型EGFR遺伝子では、EGFR遺伝子の特定の塩基に置換、欠失、挿入が生じ、下流の細胞内シグナル伝達経路が構成的に活性化状態にある機能獲得型となることによって発生すると考えられている(Paez G.J. et al., Science, 2004, 304;1497-1500)。
本実施形態の優性変異遺伝子発現抑制剤の一例として、フィラデルフィア染色体における転座変異によって生じたBCR-ABLキメラ遺伝子の発現を特異的に抑制するRNAi分子(BCR-ABL-RNAi分子)を有効成分とするBCR-ABLキメラ遺伝子発現抑制剤が挙げられる。ここでいうBCR-ABLキメラ遺伝子とは、後天的に発生する優性変異遺伝子で、慢性骨髄性白血病(CML)又は急性リンパ性白血病(ALL)の原因遺伝子とみなされている。
本実施形態の遺伝子発現抑制剤によれば、有効成分のRNAi分子は、非標的遺伝子の発現に対しては、ほとんど影響を及ぼすことなく、標的遺伝子の発現を選択的、かつ効率的に抑制することができる。
本発明の第2の実施形態は、医薬組成物である。
本発明の医薬組成物は、有効成分として前記実施形態1の優性変異遺伝子発現抑制剤を含有する。優性変異遺伝子発現抑制剤は、標的とする優性変異遺伝子に対するRNAi分子又はそのRNAi分子をコードするDNAを動作可能なように連結した発現ベクターを、単独で含んでいても良いし、同一遺伝子を標的とする一以上の異なるRNAi分子及び/又は一以上の異なるRNAi分子をコードするDNAを動作可能なように連結した発現ベクターを含んでいてもよい。
本実施形態の医薬組成物は、目的とする疾患の治療のために製薬上有効な量を生体に投与することができる。投与する対象となる生体は、脊椎動物、好ましくは哺乳動物、より好ましくはヒトである。
本発明の医薬組成物は、疾患の治療用として使用される。例えば、常染色体優性遺伝疾患のような優性変異遺伝子の発現を原因とする疾患において適用することで、その変異遺伝子の発現を選択的に抑制し、同時に正常な機能を有する遺伝子タンパク質をコードする野生型遺伝子の形質を顕在化できることから、従来その治療が困難であった遺伝病や癌等の治療の他、動植物の品種改良等に利用することができる。したがって、本実施形態の医薬組成物の対象となる疾患は、抑制剤に含まれるRNAi分子又は発現ベクターから発現されるRNAi分子が、標的とする優性変異遺伝子の優性形質に基づく疾患である。このような疾患の具体例としては、例えば、後天的に特定の細胞内のゲノムDNA中に生じた突然変異による疾患や常染色体優性変異疾患を含む。これらの疾患の具体的な例については、前述の通りである。したがって、本実施形態の医薬組成物は、治療対象となる疾患に応じて、その原因遺伝子である優性変異遺伝子に対するRNAi分子又はそれをコードするDNAを含む発現ベクターを有効成分として用いることで、様々な疾患に対して適用できる。
変異型EGFR(上皮成長因子受容体)遺伝子の発現を特異的に抑制するsiRNA(EGFR-siRNA)を設計し、変異遺伝子(癌原因遺伝子)に対する発現抑制効果、すなわちASP-RNAi(アレル特異的遺伝子サイレンシング:allele-specific RNAi)効果について検証した。
非小細胞肺癌患者では、EGFR遺伝子(アクセッションNo.NM_005228)内に疾患と関連する様々な変異(機能獲得型変異)が見つかっている。例えば、図8-1Aで示すような2235番目から2249番目(開始コドンのAを1番目とする。以下、同じ)の塩基配列が欠失した「del(E746-A750)変異」(前記遺伝子の欠失変異に伴い、開始メチオニンを1番目としたときに746番目のグルタミン酸から750番目までのアラニンが欠失した変異タンパク質を生じる)、図9-1Aで示すような2240番目から2251番目までの塩基配列が欠失した「del(L747-T751)-L747S変異」(前記遺伝子の欠失変異に伴い、747番目のロイシンから751番目のトレオニンが欠失し、また747番目のロイシンがセリンに置換された変異タンパク質を生じる)、図10-1Aで示すような2238番目から2248番目の塩基配列が欠失し、その欠失部位に新たに2塩基が挿入された「del(L747-E749)-A750P(G)変異」(前記遺伝子の欠失/挿入変異に伴い、747番目のロイシンから749番目までのグルタミン酸が欠失し、750番目のアラニンがプロリンに置換された変異タンパク質を生じる)、さらに図11-1Aで示すような開始コドンのAから2238番目に相当する塩基、すなわちE746をコードするコドン(GAG)の三番目の塩基が「G」(Pao et al., 2005, PloS Medicine, Vol. 2, Issue 3: e73)ではなく「A」(Paez et al.,2004、 Science, vol.304, 1497-1500)である「del(L747-E749)-A750P(A)変異」等がある。そして、その他、点突然変異も挙げられる。
上記del(E746-A750)変異、del(L747-T751)-L747S変異及びdel(L747-E749)-A750P変異については、その変異遺伝子産物(変異mRNA)上で、それぞれ図8-1A、9-1A, 10-1A及び11-1Aにおいて矢頭で示した位置に相当する箇所が本明細書に記載の不連続接合点に相当する。すなわち、del(E746-A750)変異遺伝子及びdel(L747-T751)-L747S変異遺伝子の転写産物では不連続接合点がそれぞれ一箇所、またdel(L747-E749)-A750P変異遺伝子の転写産物では二箇所存在することとなる。そこで、この不連続接合点に隣接する5’側及び3’側の塩基をそれぞれ第1及び第2基準塩基とした(基準塩基設定工程)。del(L747-E749)-A750P変異遺伝子の転写産物は、2つの不連続接合点を有し、かつそれらが僅か1塩基(L747-E749)-A750P(A)の場合)又は2塩基(L747-E749)-A750P(G)の場合)を挟んで近接している。それ故、ここでは、形式的に3’側に位置する不連続接合点に隣接する5’側及び3’側の塩基をそれぞれ第1及び第2基準塩基とした。次に、第2基準塩基に対応する塩基から3’末端までの塩基数を一つずつずらして、RNAiセンス鎖領域の3’末端塩基を設定した(3’末端塩基設定工程)。続いて、各変異遺伝子において、その転写産物の第1及び第2基準塩基を含む連続する19塩基を含む塩基配列をRNAiセンス鎖領域として設定した(RNAiセンス鎖領域設定工程)。また、設定されたRNAiセンス鎖領域の塩基配列に相補的な塩基配列を含む塩基配列をRNAiアンチセンス鎖領域とした(RNAiアンチセンス鎖領域設定工程)。
前記(1)で調製したEGFR-siRNAのRNAi効果の評価の選定のために、ホタル・ルシフェラーゼ(Photinus luciferase)遺伝子を発現するpGL3-TK (Ohnishi Y., et al., 2006, Journal of RNAi and Gene Silencing, Vol. 2: 154-160)と及びウミシイタケ・ルシフェラーゼ(Renilla luciferase)遺伝子を発現するphRL-TK プラスミド(Promega社)を用いて、siRNAの標的となる優性変異遺伝子と非標的の野生型遺伝子のレポーター遺伝子発現プラスミドの構築を行った。
ヒト由来株化細胞であるHeLa細胞を10%ウシ胎仔血清(FBS;Invitrogen社)及び抗生物質(100ユニット/mL ペニシリン、100μg/mLストレプトマイシン;Wako社)含有のDMEM培養液(Wako社)を用いて、5% CO2下で37℃にて培養した。
前記レポーター遺伝子発現プラスミドを用いたレポーターアッセイによって様々なEGFR-siRNAのRNAi効果及びRNAi誘導に好適なRNAi分子の構造的一般法則性について検討した。
del(E746-A750)変異遺伝子に対する各EGFR-siRNAの結果を図8-1Bに、del(L747-T751)-L747S変異遺伝子に対する各EGFR-siRNAの結果を図9-1Bに、そしてdel(L747-E749)-A750P(G)、及びdel(L747-E749)-A750P(A)変異遺伝子に対する各EGFR-siRNAの結果をそれぞれ図10-1B、及び図11-1Bに、示す。各図において、非標的の野生型EGFR遺伝子と、標的の変異型EGFR遺伝子のルシフェラーゼ活性を、それぞれのsiControlのルシフェラーゼ活性を1.0としたときの相対値として算出した。各サンプルのルシフェラーゼ活性は、RNAiによる発現抑制を受けない外来性コントロールであるβ-ガラクトシダーゼの発現量で補正している。
前記実施例1で、変異型EGFR、すなわち、del(E746-A750)、del(L747-T751)-L747S、del(L747-E749)-A750Pに対して効果的な発現抑制効果を示したEGFR-siRNAについて、それらが内在性の変異型EGFRに対しても特異的な発現抑制効果(ASP-RNAi効果)を示すか否かを検討した。本実験にはEGFR del(L747-E749)-A750Pを有するヒト肺癌由来のPC3細胞を例として使用した。EGFR-siRNAには、実施例1においてdel(L747-E749)-A750P変異に対して、特に発現抑制効果のあったsi747/49-3D19、及びsi747/49(A)-8D19を用いて内在性変異型EGFRのRNAiノックダウンを行った。
(1)細胞培養
ヒト非小細胞肺癌由来株化細胞であるPC3細胞を10%ウシ胎仔血清(FBS;Invitrogen社)含有のEMEM培養液(Wako社)を用いて、5% CO2下で37℃にて培養した。
前記(1)で培養した細胞をトリプシン消化によって分散させた後、遠心(120G、5分間)によって回収し、約1×106個の細胞をEGFR-siRNA(終濃度5μM)を含む100μLのエレクトロポレーションバッファ(Amaxa Cell Line Nucleofector Solution V、Amaxa社)にて懸濁した。前記エレクトロポレーション用サンプルを3つ調製し、添付されたプロトコールに従ってエレクトロポレーション(プログラム:U-005, 遺伝子導入システムNucleofector, Amaxa社)によって核酸の導入(1つは核酸を入れない対照実験群)を行なった。導入した核酸は、si747/49-3D19、si747/49(A)-8D19と RNAiを誘導しないコントロールsiRNA(QIAGEN社)である。
前記(2)で回収した細胞をTRIzol reagent (Invitrogen社)を用いて、添付されたプロトコールに従って全RNAを回収した。その後、SuperScript III Reverse Transcriptase (Invitrogen社)及びOligo(dT)15 (Promega社)を用いて逆転写酵素反応によってcDNAを合成し、その後RNaseH (Invitrogen社)処理を行った。前記操作は全て添付されたプロトコールに従い行った。
前記(3)で得たcDNAをAmpliTaq Gold DNA Polymerase (アプライドバイオシステム社)とEGFR変異部位周辺配列を特異的に増幅するプライマーを用いてPCR解析を行った。PCRの温度・時間条件は、初期変性(95℃、10分)後、変性(94℃、30秒)、アニール(55℃、30秒)、伸長反応(72℃、30秒)の3段階を26回繰返す条件とした。その後、PCR増幅産物を電気泳動法(7%ポリアクリルアミドゲル、100mA、1時間)にて解析した。使用したプライマー配列は、表7に示す。
si747/49-3D19での結果を図14に、si747/49(A)-8D19での結果を図15にそれぞれ示す。どちらのEGFR-siRNAも、野生型EGFR遺伝子の発現を抑制することなく、内在性変異型EGFR遺伝子の発現を特異的、かつ強力に抑制することが実証された。
実施例2で示した、EGFR-siRNA(si747/49-3D19、及びsi747/49(A)-8D19)を用いた内在性変異型EGFR(del(L747-E749)-A750P)の特異的かつ効果的な発現抑制が細胞増殖や細胞死に対して影響を与え得るか否かを、全細胞数、細胞毒性、細胞増殖・生存活性、細胞死(アポトーシス)に関して、それぞれ検討した。
前記「実施例2(1)」と同様にPC3細胞の培養を行った。
前記「実施例2(2)」と同様に、エレクトロポレーションを行った。
[方法]
si747/49-3D19導入後のPC3細胞における経時的な細胞数の変化(細胞増殖能)を調べるため、細胞内LDH(Lactate Dehydrogena;乳酸脱水素酵素)量をCytoTox 96(R) Non-Radioactive Cytotoxicity Assay (Promega社)を用いて測定した。実験は、添付されたプロトコールに従って行った。簡潔には、前記アッセイキットに添付された細胞溶解バッファ(Lysis Solution (10x))を全サンプル群の培養液に加え、45分間37℃でインキュベートすることによって全細胞に含有される全てのLDHが放出される。このLDH量を測定することで全細胞数を間接的に算出した。吸光度の測定はBenchMark Plus (BIO-RAD社)を用いた。ネガティブコントロールには、siRNAを加えないサンプル(siRNAなし)とRNAiを誘導しないsiRNA(siControl; QIAGEN社)を添加したサンプルを用いた。
図16に結果を示す。この図では、全細胞数とみなす1日目の「siRNAなし」のLDH量を100%としたときのLDH量の相対値(%)で示した。EGFR-siRNA(si747/49-3D19)は、「siRNAなし」に対しても、また「siControl」に対しても有意にPC3細胞のその全細胞数を減少させた。すなわち、この結果はsi747/49-3D19がPC3細胞の細胞増殖を抑制したことを意味する。また、同時に、構成的活性化により細胞増殖活性を促進するPC3内在性優性変異型EGFR(del(L747-E749)-A750P)遺伝子に対してsi747/49-3D19が特異的かつ効果的に、その発現を抑制したことを示している。
[方法]
si747/49-3D19導入後のPC3細胞における細胞毒性を評価するため、細胞毒性によって細胞外に放出され、培養液中に存在するLDH量をCytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega社)を用いて測定した。実験操作は、添付されたプロトコールに従って行い、吸光度の測定は、BenchMark Plus (BIO-RAD社)を用いた。また、使用したネガティブコントロールは、前記細胞増殖能の測定時に使用したものと同じ2つのコントロール(siRNAなし及びsiControl)を用いた。
図17に結果を示す。この図では、1日目の「siRNAなし」の全細胞が含有するLDH量(前記細胞増殖能評価実験と同様に細胞溶解バッファを添加したサンプル)を100%としたときの相対値(%)で示している。si747/49-3D19は、「siRNAなし」や「siControl」と同等又はそれ以上に細胞毒性、又は内在性変異型EGFRの発現抑制による細胞死を誘導しないことが明らかとなった。
[方法]
si747/49-3D19導入後のPC3細胞における細胞増殖及び生存活性を評価するために、CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega社)を用いて、生細胞に含まれるNADH(nicotinamide adenine dinucleotide;ニコチンアミドアデニンジヌクレオチド)によるMTS還元作用を測定した。実験操作は、添付されたプロトコールに従って行い、吸光度の測定はBenchMark Plus (BIO-RAD社)を用いた。また、使用したネガティブコントロールは、前記細胞増殖能の測定時に使用したものと同じ2つのコントロール(siRNAなし及びsiControl)を用いた。
si747/49-3D19の結果を図18、si747/49(A)-8D19の結果を図19にそれぞれ示す。この図では、細胞増殖及び生存活性(細胞生存率)を「siRNAなし」の1日目のNADH活性を100%としたときの相対値として示している。si747/49-3D19、及びsi747/49(A)-8D19は、「siRNAなし」及び「siControl」のいずれに対しても有意にその増殖率を抑制し、又は生存率を低下させた。
[方法]
si747/49-3D19導入後のPC3細胞における細胞増殖及び生存活性を評価するため、CellTiter-Glo Assay (Promega社)を用いて、細胞の相対的ATP量を測定した。実験操作は添付されたプロトコールに従って行い、発光量の測定はFusion Universal Microplate Analyzer(Perkin Elmer社)を用いた。また、使用したネガティブコントロールは、前記細胞増殖能の測定時に使用したものと同じ2つのコントロール(siRNAなし及びsiControl)を用いた。
図20に結果を示す。細胞増殖及び生存活性(細胞生存率)は、「siRNAなし」の培養1日目の相対的ATP量を100%としたときの、1日目と4日目の相対値を示している。この図が示すように、si747/49-3D19は、培養4日目には「siRNAなし」及び「siControl」のいずれに対しても有意にその増殖率を抑制し、又は生存率を低下させた。
[方法]
si747/49-3D19導入後のPC3細胞おける細胞死(アポトーシス)評価のため、Caspase-Glo 3/7 Assay (Promega社)を用いてcaspase3/7の活性を測定した。実験操作は、添付されたプロトコールに従って行い、発光量の測定は、Fusion Universal Microplate Analyzer (Perkin Elmer社)を用いた。また、使用したネガティブコントロールは、前記細胞増殖能の測定時に使用したものと同じ2つのコントロール(siRNAなし及びsiControl)を用いた。
図21に結果を示す。caspase3/7活性は、「siRNAなし」の培養1日目の活性を100%としたときの、1日目と4日目の相対値を示している。この図が示すように、si747/49-3D19は、培養4日目の「siRNAなし」及び「siControl」のいずれと比較してもcaspase3/7活性に有意な変化を示さなかった。これは、si747/49-3D19による変異型EGFR特異的発現抑制がアポトーシスを誘導しないことを示している。
(1)EGFR遺伝子に対するEGFR-siRNAのASP-RNAi効果の検討
[方法]
実施例1で記載したように、非小細胞肺癌患者では、EGFR遺伝子内に疾患と関連する機能獲得型変異として、点突然変異も知られている(Paez G.J. et al., Science, 2004, 304;1497-1500)。例えば、図22Aで示すような2369番目の塩基CがTに置換した「T790M変異」(前記遺伝子の点突然変異に伴い、790番目のトリプトファンがメチオニンにアミノ酸変化(T790M)する点突然変異が挙げられる。このような点突然変異による置換変異を有する変異遺伝子は、その転写産物が不連続接合点を有さないことから、本願実施例1の優性変異遺伝子発現抑制剤の対象とはならない。
前記1で調製したEGFR-siRNAのRNAi効果の評価の選定のために、siRNAの標的となる優性変異遺伝子と非標的の野生型遺伝子のレポーター遺伝子発現プラスミドの構築、細胞培養、トランスフェクション及びレポーターアッセイを行なった。基本的な操作手順は、実施例1に記載の方法に準じた。
結果を図22Bに示す。この図が示すように、si790-9C/U18は、siControlと比較して野生型EGFR遺伝子の発現にも比較的強い抑制効果があることからあまり好ましいsiRNAではなかったが、si790-10C/U18とsi790-11C/U18は、野生型EGFR遺伝子に対する発現抑制効果がほとんどなく、一方、変異型EGFR遺伝子に対しては効果的な抑制作用を有することが明らかとなった。
フィラデルフィア染色体における転座変異によって生じたBCR-ABLキメラ遺伝子を標的とする本実施形態1の構成を有するsiRNA(BCR-ABL-siRNA)を設計し、白血病原因遺伝子であるBCR-ABLキメラ遺伝子に対する発現抑制効果について検証した。
前述のように、BCR-ABLキメラ遺伝子は、フィラデルフィア染色体を有する患者で見出されるCMLやALLの原因遺伝子とみなされており、本発明のBCR-ABL-siRNAが機能亢進型のBCR-ABL遺伝子の発現のみを特異的に抑制することができれば、フィラデルフィア染色体を有する患者でCMLやALLに対する効果的な予防剤又は治療剤となり得る。
Ph転座におけるBCR遺伝子の切断点は、Major-BCR(下流:M-BCR)とminor-BCR(上流:m-BCR)の二箇所に集中していることが知られているが、慢性好中球性白血病/本態性血小板血症では、さらに下流のμ-BCR(p230)の関与が報告されている。それぞれp210BCR/ABL(M-BCR切断点)、p190BCR/ABL(m-BCR切断点)、p230BCR/ABL(μ-BCR切断点)の蛋白が生じ、このうちp210BCR/ABLはCMLのほぼ全例及びPh陽性ALLに、p190BCR/ABLはPh陽性ALLの残り半数の患者に認められる。
上記M-BCRを切断点とするBCR-ABLキメラ遺伝子については、その変異遺伝子産物(変異mRNA)上で、野生型ABL遺伝子と野生型BCL遺伝子のそれぞれに対して図12-1A、及び13-1Aにおいて矢頭で示した位置に相当する箇所が本明細書に記載の不連続接合点に相当する。この不連続接合点に隣接する5’側及び3’側の塩基をそれぞれ第1及び第2基準塩基として、実施例1と同様の方法によりBCR-ABL-siRNAの設計し、調製した。
レポーター遺伝子発現プラスミドの構築、変異部位を含む合成オリゴDNAの設計、レポーター遺伝子発現プラスミドへの挿入、選定方法については、実施例1の「(3)レポーター遺伝子発現プラスミドの構築」に記載の方法に準じた。使用した合成オリゴDNAの具体的な塩基配列を表10に示す。
実施例1の「(4)細胞培養」に記載の方法に準じた。
実施例1の「(5)トランスフェクション及びレポーターアッセイ」に記載の方法に準じた。
BCR-ABLキメラ遺伝子に対する各BCR-ABL-siRNAの結果を図12-1B及び図13-1Bに示す。各BCR-ABL-siRNAの該遺伝子に対する特異的発現抑制効果を評価するためには、BCR-ABLキメラ遺伝子と二つの野生型遺伝子(ABL遺伝子とBCR遺伝子)に対して評価しなければならない。そのため、各BCR-ABL-siRNAの標的遺伝子特異的発現抑制効果をBCR-ABLキメラ遺伝子と野生型ABL遺伝子(図12-1B)、そしてBCR-ABLキメラ遺伝子と野生型BCR遺伝子(図13-1B)の組み合わせで評価した。また前記と同様に、各図において、非標的の野生型ABL又はBCR遺伝子と、標的のBCR-ABLキメラ遺伝子のルシフェラーゼ活性を、それぞれのsiControlのルシフェラーゼ活性を1.0としたときの相対値として算出した。各サンプルのルシフェラーゼ活性は、RNAiによる発現抑制を受けない外来性コントロールであるβ-ガラクトシダーゼの発現量で補正している。
前記実施例1でEGFRのdel(L747-E749)-A750P変異又はdel(E746-A750)変異に対してそれぞれ特異的な発現抑制を示したEGFR-siRNA、及び変異型EGFRを発現する非小細胞肺癌に対して有効とされる抗癌剤ゲフィチニブを用いて、それぞれの細胞増殖及び細胞生存活性に対する影響について検証した。
(1)細胞培養
解析には、EGFRのdel(L747-E749)-A750P変異及びdel(E746-A750)変異を有するヒト非小細胞肺癌由来株化細胞であるPC3細胞及びPC9細胞、及び対照用に野生型EGFRを有するヒトHeLa細胞を用いた。PC3細胞の培養は、前記「実施例2:(1)」と、またHeLa細胞の培養は、前記「実施例1:(4)」と同様に行った。PC9細胞は、10%ウシ胎仔血清(FBS;Invitrogen社)含有のRPMI-1640培養液(Wako社)を用いて、5% CO2下で37℃にて培養した。
培養したPC3細胞、PC9細胞及びHeLa細胞を、トリプシン消化によって分散させた後、遠心(120G、5分間)によって回収し、96ウェル培養プレートにて細胞培養(細胞密度:約1×105個/cm2)を行った。24時間後、終濃度0、10-3、10-2、10-1、100及び101μMのゲフィチニブ(商品名:イレッサ;アストラゼネカ社)に曝露し、3日後に細胞生存活性を測定した。
前記「実施例2:(2)」と同様の方法で、EGFR-siRNAの細胞導入を行った。具体的には、前記(1)の培養液で培養したPC3細胞をトリプシン消化によって分散させた後、遠心(120G、5分間)によって回収し、約1×106個の細胞を、終濃度100、50、25、10、5、1及び0nMのEGFR-siRNA(si747/49-3D19)又はRNAiを誘導しないsiRNA(siControl; QIAGEN社)を含む100μLのエレクトロポレーションバッファ(Amaxa Cell Line Nucleofector Solution V、Amaxa社)にて懸濁した。添付されたプロトコールに従ってエレクトロポレーション(プログラム:U-005, 遺伝子導入システムNucleofector, Amaxa社)を行い、前記siRNAを細胞に導入した。「実施例2:(1)」に記載の培地で培養し、3日後に細胞生存活性を測定した。
前記(1)96ウェル培養プレートにて細胞培養(細胞密度:約1×105個/cm2)を行った。終濃度100、50、25、10、5、1及び0nMのEGFR-siRNA (si746/50-4D19)及びRNAiを誘導しないsiRNA(siControl; QIAGEN社)を、リポフェクタミン2000(Invitrogen社)を用いてPC9細胞に導入した。トランスフェクション法は、添付されたプロトコールに従った。培養3日後に細胞生存活性を測定した。
前記「実施例3;3.細胞増殖及び生存活性評価(1)」と同様の方法で評価した。
(1)細胞増殖及び生存活性に対するゲフィチニブの影響
ゲフィチニブによる各細胞の細胞増殖及び生存活性の結果を図23A~Cに示す。図23Aは、del(L747-E749)-A750P変異を有するPC3細胞の、図23Bは、del(E746-A750)変異を有するPC9細胞の、図23CはHeLa細胞の結果である。各図は、それぞれ無処置の細胞における細胞生存活性を100%としたときの相対値を示している。
EGFR-siRNAによる各細胞の細胞増殖及び生存活性結果を図24A~Cに示す。
細胞レベルで検証したEGFR-siRNAの効果を個体レベルで検証した。
ヌードマウスの皮下にPC3細胞を移植し、マウス皮下腫瘍モデルを作出し、そのモデルマウスを用いてEGFR-siRNA投与による腫瘍成長阻害効果を検証した。
(i)細胞培養
前記「実施例2:(1)」と同様の方法でPC3細胞を培養した。
培養したPC3細胞を、トリプシン消化によって分散させた後、遠心(120G、5分間)によって回収し、血清及び抗生物質不含の培養液(RPMI-1640、Wako社)で再懸濁し、細胞数1×107cells/mLに調製した。この細胞懸濁液と、BDマトリゲル基底膜マトリックス(ベクトン・ディッキンソン社)を等量混ぜ合わせ、細胞数5×106cells/mLに調製した。これを、免疫不全モデルのヌードマウス(5週齢、BALB/cAJcl-nu/nu、日本クレア株式会社)の右側腹部に100μL(0.5×106cells)で皮下投与した。
(i)EGFR-siRNAの調製と投与
アテロコラーゲンを主成分とする核酸デリバリー媒体であるAteloGene(登録商標) Local Use(株式会社 高研)と、実施例1~3でPC3細胞に対して効果的な細胞増殖抑制効果を示したsi747/49-3D19、又はsi747/49(A)-8D19との複合体を調製した。調製法は、添付されたプロトコールに従い、EGFR-siRNA(si747/49-3D19、又はsi747/49(A)-8D19)の終濃度は、0.1mg/mLとした。対照実験としてRNAiを誘導しないsiRNA(siControl; QIAGEN社)も同様に調製し、siRNAを含まないアテロコラーゲン液も調製した。
PC3細胞を移植して1週間後(6週齢)に腫瘍径より腫瘍体積を算出し、約50mm3に達した腫瘍に対して、前記で調製した3つのサンプル、すなわちsiRNA不含のアテロコラーゲン溶液、siControl及びEGFR-siRNAの20μg/200μL溶液を、それぞれ1.0mg/kg体重で腫瘍に直接単回投与した。腫瘍体積は、以下の式を用いて計算した。
(iii)siRNA投与後の経過観察
siRNA等の投与3週目(9週齢)(図25A、si747/49-3D19;図28A、si747/49(A)-8D19)に、前記計算式により腫瘍体積を測定し、さらに腫瘍を取り出して(図25B、si747/49-3D19;図28B、si747/49(A)-8D19)、湿重量を計測した。
EGFR-siRNAの投与による腫瘍体積の時間経過を図26(si747/49-3D19投与)、図29(si747/49(A)-8D19投与)に、摘出した腫瘍の湿重量を図27(si747/49-3D19投与)、図30(si747/49(A)-8D19投与)に、それぞれ示す。EGFR-siRNA(si747/49-3D19、又はsi747/49(A)-8D19)を投与した個体群は、アテロコラーゲン溶液のみ及びsiControlを投与した個体群と比較して、皮下腫瘍の肥大が有意に抑制されることが示された。さらに、腫瘍の湿重量もそれらと比較して有意に低下していた。
上述の実施例で立証したように、本発明のEGFR-siRNAは変異型のEGFR遺伝子のみを特異的に発現抑制するのに対して、従来のsiRNAは野生型及び変異型のEGFR遺伝子を区別せず両者を強く発現抑制する。そこで、本発明のEGFR-siRNAと従来のsiRNAをマウス個体に投与した場合の副作用の有無について検証した。
ICRマウス(雄、10週齢)の腹腔内に各種siRNAを投与した。実験群は、siRNAを投与しないアテロコラーゲン溶液のみの群(siRNAなし)と、RNAiを誘導しないsiRNA(siControl; QIAGEN社)、変異型EGFR遺伝子を特異的に発現抑制するsi747/49-3D19、及びマウス生体内で発現している内在性野生型EGFR遺伝子を発現抑制するsiEgfrをぞれぞれ投与した、計4群である。これらは、前記実施例7と同様の方法で調製し、マウス腹腔内に投与した。なお、本実施例で設計し、使用したsiEgfrの具体的な塩基配列を表11に示す。
図31に結果を示す。血漿中の全ビリルビン(A)、直接ビリルビン(B)、間接ビリルビン(C)、及びアルカリホスファターゼ(D)の量に関して、siRNAなし群及びsiControl投与群と比較すると、内在性野生型EGFR遺伝子を発現抑制するsiEgfr投与群では、有意な上昇が観察された。一方、本発明のEGFR-siRNA(si747/49-3D19)投与群では、有意な変化は観察されなかった。この血中パラメーターの有意な上昇は、siEgfrの投与によって内在性野生型EGFRの発現が抑制されたことに起因し、変化した血中パラメーターのデータから肝胆道系の障害が惹起されたことが示唆された。また、内在性野生型EGFR遺伝子が肝細胞の再生に必要であることから(Natarajan et al., 2007, Proc Natl Acad Sci U S A., Vol. 104: 17081-17086)、まとめると、内在性野生型EGFR遺伝子の発現抑制は重篤な副作用をひき起こす危険性があることが示唆された。それに対して、本発明のEGFR-siRNAの投与は、血中パラメーターに全く影響せず、内在性野生型EGFR遺伝子の発現にほとんど影響を及ぼさないことが立証された。この結果は、本発明のEGFR-siRNAが、従来のEGFR-siRNAとは異なり、上記のような肝胆道系の障害等の副作用を生じる危険性がないか、又は極めて低いことを示唆している。これにより、本発明の優性変異遺伝子の発現抑制剤のRNA干渉技術の有用性が立証された。
Claims (23)
- ASPスコア値が0.4以上であるRNAi分子を有効成分として含む、優性変異遺伝子の発現抑制剤であって、
前記ASPスコアは、以下の式から算出され、
ASPスコア=[(対照RNAi分子で処理した正常型遺伝子の標準化した発現量に対する前記RNAi分子で処理した正常型遺伝子の標準化した発現量の相対比)-(対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)]×(1-対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)
(式中、対照RNAi分子は、前記正常型遺伝子及び変異遺伝子の発現に影響を及ぼさないRNAi分子である)
前記RNAi分子が
標的である優性変異遺伝子の転写産物上に生じる少なくとも一つの不連続接合点、及び該転写産物の連続する16~30塩基の配列に一致する塩基配列を含むRNAiセンス鎖領域、並びにそれに相補的な塩基配列を含むRNAiアンチセンス鎖領域を含み、かつ
前記RNAiセンス鎖領域上のいずれか一の不連続接合点に隣接する3’側の塩基から下流側に向かって4~15番目のいずれか一の塩基が該RNAiセンス鎖領域の3’末端塩基を構成する、
前記遺伝子発現抑制剤。 - ASPスコア値が0.4以上であるRNAi分子をコードするDNAを動作可能なように連結した発現ベクターを有効成分として含む、優性変異遺伝子の発現抑制剤であって、
前記ASPスコアは、
以下の式から算出され、
ASPスコア=[(対照RNAi分子で処理した正常型遺伝子の標準化した発現量に対する前記RNAi分子で処理した正常型遺伝子の標準化した発現量の相対比)-(対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)]×(1-対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)
(式中、対照RNAi分子は、前記正常型遺伝子及び変異遺伝子の発現に影響を及ぼさないRNAi分子である)
前記RNAi分子が
標的である優性変異遺伝子の転写産物上に生じる少なくとも一つの不連続接合点、及び該転写産物の連続する16~30塩基の配列に一致する塩基配列を含むRNAiセンス鎖領域、並びにそれに相補的な塩基配列を含むRNAiアンチセンス鎖領域を含み、かつ
前記RNAiセンス鎖領域上のいずれか一の不連続接合点に隣接する3’側の塩基から下流側に向かって4~15番目のいずれか一の塩基が該RNAiセンス鎖領域の3’末端塩基を構成する、
前記遺伝子発現抑制剤。 - RNAiセンス鎖領域及びRNAiアンチセンス鎖領域の3’末端にさらにTT又はUUを付加する、請求項1又は2に記載の抑制剤。
- RNAi分子がsiRNAである、請求項1~3のいずれか一項に記載の抑制剤。
- RNAi分子がshRNAである、請求項1~3のいずれか一項に記載の抑制剤。
- 優性変異遺伝子における変異が塩基の欠失、塩基の挿入、スプライス部位を破壊し得る塩基の置換、遺伝子の重複、遺伝子の転座、及び染色体の逆位からなる一群から選択される、請求項1~5のいずれか一項に記載の抑制剤。
- 優性変異遺伝子が機能獲得型である、請求項1~6のいずれか一項に記載の抑制剤。
- 優性変異遺伝子が疾患の発症に関与する、請求項1~7のいずれか一項に記載の抑制剤。
- 疾患が悪性新生物である、請求項8に記載の抑制剤。
- 悪性新生物が非小細胞肺癌で、かつその標的となる前記優性変異遺伝子が変異型EGFR遺伝子であるか、悪性新生物が大腸癌で、かつその標的となる前記優性変異遺伝子が変異型CTNNB1遺伝子であるか、悪性新生物が胃癌で、かつその標的となる前記優性変異遺伝子が変異型CDH1遺伝子であるか、悪性新生物が乳癌で、かつその標的となる前記優性変異遺伝子が変異型BRCA1遺伝子若しくは変異型BRCA2遺伝子であるか、悪性新生物が多腺性自己免疫性内分泌不全症I型で、かつその標的となる前記優性変異遺伝子が変異型AIRE遺伝子であるか、悪性新生物が自己免疫性リンパ増殖症候群で、かつその標的となる前記優性変異遺伝子が変異型TNFRSF6/APT1/FAS遺伝子であるか、悪性新生物が慢性骨髄性白血病又は急性リンパ性白血病で、かつその標的となる前記優性変異遺伝子がBCR-ABLキメラ遺伝子であるか、悪性新生物がバーキットリンパ腫で、かつその標的となる前記優性変異遺伝子がc-myc-IgH-キメラ遺伝子であるか、悪性新生物が未分化型大細胞リンパ腫で、かつその標的となる前記優性変異遺伝子がNPM-ALK-キメラ遺伝子であるか、悪性新生物が肺癌で、かつその標的となる前記優性変異遺伝子がEML4-ALK-キメラ遺伝子であるか、悪性新生物が隆起性皮膚線維肉腫で、かつその標的となる前記優性変異遺伝子がPDGFB-COL1A1キメラ遺伝子であるか、悪性新生物が先天性線維肉腫で、かつその標的となる前記優性変異遺伝子がETV6-NTRK3キメラ遺伝子であるか、悪性新生物が低悪性線維粘液肉腫で、かつその標的となる前記優性変異遺伝子がFUS-CREB3L2キメラ遺伝子であるか、悪性新生物が骨外性粘液型軟骨肉腫で、かつその標的となる前記優性変異遺伝子がEWS-CHNキメラ遺伝子であるか、悪性新生物がユーイング肉腫若しくは線維形成性小細胞腫瘍で、かつその標的となる前記優性変異遺伝子がEWSR1遺伝子を転座パートナーとするキメラ遺伝子であるか、悪性新生物が胞巣型横紋筋肉腫で、かつその標的となる前記優性変異遺伝子がSYT遺伝子若しくはSSX遺伝子を転座パートナーとするキメラ遺伝子であるか、悪性新生物が炎症性筋線維芽細胞性腫瘍で、かつその標的となる前記優性変異遺伝子がALK遺伝子を転座パートナーとするキメラ遺伝子であるか、悪性新生物が脂肪肉腫で、かつその標的となる前記優性変異遺伝子がCHOP遺伝子を転座パートナーとするキメラ遺伝子であるか、又は悪性新生物が軟部明細胞肉腫若しくは悪性線維性組織球腫で、かつその標的となる前記優性変異遺伝子がATF1遺伝子を転座パートナーとするキメラ遺伝子である、請求項9に記載の抑制剤。
- 悪性新生物が非小細胞肺癌で、かつその標的となる前記優性変異遺伝子が変異型EGFR遺伝子である、請求項10に記載の抑制剤。
- RNAi分子のセンス鎖領域が、配列番号3、5、7、9、11、13、15、17、19、21、29、31、33、35、37、39、41、43、45、47、49、53、55、59、61、63、65、67、129、131、133、135、137、139、141、143又は145で示されるヌクレオチドからなる、請求項11に記載の抑制剤。
- 悪性新生物が慢性骨髄性白血病又は急性リンパ性白血病で、かつその標的となる前記優性変異遺伝子がBCR-ABLキメラ遺伝子である、請求項10に記載の抑制剤。
- RNAi分子のセンス鎖領域が、配列番号97、99、101、103、105、107、109、111又は113で示されるヌクレオチドからなる、請求項13に記載の抑制剤。
- 疾患がヒト常染色体優性変異疾患である、請求項8に記載の抑制剤。
- ヒト常染色体優性変異疾患が先天性夜盲症で、かつその標的となる前記優性変異遺伝子がRHO遺伝子であるか、ヒト常染色体優性変異疾患が難聴遺伝子領域DFNA2で、かつその標的となる前記優性変異遺伝子がKCNQ4遺伝子若しくはGJB遺伝子であるか、ヒト常染色体優性変異疾患がワールデンブルグ症候群で、かつその標的となる前記優性変異遺伝子がMITF遺伝子であるか、ヒト常染色体優性変異疾患が非症候性難聴で、かつその標的となる前記優性変異遺伝子がDIAPH1/DFNA1遺伝子若しくはPOU4F3遺伝子であるか、ヒト常染色体優性変異疾患が肥大型心筋症で、かつその標的となる前記優性変異遺伝子がTNNT2遺伝子であるか、ヒト常染色体優性変異疾患が家族性肥大型心筋症で、かつその標的となる前記優性変異遺伝子がMYBPC3遺伝子であるか、ヒト常染色体優性変異疾患が心尖部肥大型心筋症で、かつその標的となる前記優性変異遺伝子がTNNI3遺伝子であるか、ヒト常染色体優性変異疾患がシャルコー・マリー・トゥース病1A型で、かつその標的となる前記優性変異遺伝子がPMP22遺伝子であるか、ヒト常染色体優性変異疾患がシャルコー・マリー・トゥース病1B型で、かつその標的となる前記優性変異遺伝子がMPZ遺伝子であるか、ヒト常染色体優性変異疾患がQT延長症候群で、かつその標的となる前記優性変異遺伝子がKCNQ1遺伝子若しくはKCNH2遺伝子若しくはSCN5A遺伝子若しくはANK2遺伝子若しくはKCNE1遺伝子若しくはKCNE2遺伝子若しくはKCNJ2遺伝子若しくはCAV3遺伝子若しくはSCN48遺伝子若しくはAKAP9遺伝子若しくはANTA1遺伝子であるか、ヒト常染色体優性変異疾患がQT短縮症候群で、かつその標的となる前記優性変異遺伝子がKCNH2遺伝子若しくはKCNJ2遺伝子であるか、ヒト常染色体優性変異疾患がブルガタ症候群で、かつその標的となる前記優性変異遺伝子がSCN5A遺伝子若しくはGPD1L遺伝子若しくはCACNA1C遺伝子若しくはCACNB2B遺伝子若しくはSCN1B遺伝子であるか、ヒト常染色体優性変異疾患がカテコラミン誘発性多形性心室頻拍で、かつその標的となる前記優性変異遺伝子がRYR2遺伝子であるか、ヒト常染色体優性変異疾患が心伝導障害で、かつその標的となる前記優性変異遺伝子がSCN5A遺伝子若しくはSCN1B遺伝子であるか、ヒト常染色体優性変異疾患が筋萎縮性側索硬化症で、かつその標的となる前記優性変異遺伝子がTDP43遺伝子であるか、ヒト常染色体優性変異疾患がヌーナン症候群で、かつその標的となる前記優性変異遺伝子がPTPN11遺伝子であるか、又はヒト常染色体優性変異疾患が低カルシウム血症で、かつその標的となる前記優性変異遺伝子がCaR遺伝子である、請求項15に記載の抑制剤。
- 疾患が筋硬直性ジストロフィーで、かつその標的となる前記優性変異遺伝子がDMPK遺伝子であるか、疾患が脊髄性筋萎縮症で、かつその標的となる前記優性変異遺伝子がSMN1遺伝子であるか、疾患が先天性筋無力症候群で、かつその標的となる前記優性変異遺伝子がCHRNE遺伝子であるか、疾患が前頭側頭葉型痴呆症で、かつその標的となる前記優性変異遺伝子がMAPT遺伝子であるか、又は疾患が成長ホルモン単独欠損症II型で、かつその標的となる前記優性変異遺伝子がGH1遺伝子である、請求項8に記載の抑制剤。
- 請求項1~17のいずれか一項に記載の抑制剤を有効成分として少なくとも一つ含有する医薬組成物。
- センス鎖領域が、配列番号83又は85で示されるヌクレオチドからなるRNAi分子、及び/又はそのヌクレオチドをコードするDNAを動作可能なように連結した発現ベクター、並びに/あるいはセンス鎖領域が、配列番号89で示されるヌクレオチドからなるRNAi分子、及び/又はそのRNAi分子をコードするDNAを動作可能なように連結した発現ベクターを有効成分としてさらに含有する、請求項11又は12に従属する請求項18に記載の医薬組成物。
- センス鎖領域が、配列番号89で示されるヌクレオチドからなるRNAi分子、及び/又はそのRNAi分子をコードするDNAを動作可能なように連結した発現ベクターを含む、点突然変異型EGFR遺伝子発現抑制剤。
- 転写産物上に不連続接合点を有する優性変異遺伝子の発現を選択的に抑制するRNAi分子の設計方法であって、
(a)該転写産物上の不連続接合点に隣接する5’側及び3’側の塩基をそれぞれ第1及び第2基準塩基として設定する工程、
(b)前記転写産物において、前記第2基準塩基に対応する塩基から下流側に向かって4~15番目の塩基がRNAiセンス鎖の3’末端塩基に対応するように設定する工程、
(c)前記優性変異遺伝子において、その転写産物の第1及び第2基準塩基を含む連続する16~30塩基を含む塩基配列をRNAiセンス鎖領域として設定する工程、
(d)設定されたRNAiセンス鎖領域の塩基配列に相補的な塩基配列を含む塩基配列をRNAiアンチセンス鎖領域として設定する工程
を含む、前記設計方法。 - (e)ASPスコア値が0.4以上あるRNAi分子を選別する工程をさらに含む、請求項21に記載の設計方法であって、
ASPスコアは、以下の式から算出される、前記設計方法。
ASPスコア=[(対照RNAi分子で処理した正常型遺伝子の標準化した発現量に対する前記RNAi分子で処理した正常型遺伝子の標準化した発現量の相対比)-(対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)]×(1-対照RNAi分子で処理した変異遺伝子の標準化した発現量に対する前記RNAi分子で処理した変異遺伝子の標準化した発現量の相対比)
(式中、対照RNAi分子は、前記正常型遺伝子及び変異遺伝子の発現に影響を及ぼさないRNAi分子である) - RNAiセンス鎖領域及びRNAiアンチセンス鎖領域の3’末端にさらにTT又はUUを付加する、請求項21又は22に記載の設計方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/821,299 US9238812B2 (en) | 2010-09-30 | 2011-09-28 | Agent for suppressing expression of dominant mutant gene |
EP11829186.3A EP2623600A4 (en) | 2010-09-30 | 2011-09-28 | EXPRESSION INHIBITOR OF A DOMINANTLY MUTANT GENE |
JP2012536507A JP5996431B2 (ja) | 2010-09-30 | 2011-09-28 | 優性変異遺伝子発現抑制剤 |
CN201180041884.XA CN103080314B (zh) | 2010-09-30 | 2011-09-28 | 显性突变基因表达抑制剂 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010222847 | 2010-09-30 | ||
JP2010-222847 | 2010-09-30 | ||
JP2011-044347 | 2011-03-01 | ||
JP2011044347 | 2011-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012043633A1 true WO2012043633A1 (ja) | 2012-04-05 |
Family
ID=45893072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/072187 WO2012043633A1 (ja) | 2010-09-30 | 2011-09-28 | 優性変異遺伝子発現抑制剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9238812B2 (ja) |
EP (1) | EP2623600A4 (ja) |
JP (1) | JP5996431B2 (ja) |
CN (1) | CN103080314B (ja) |
WO (1) | WO2012043633A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105264084A (zh) * | 2013-01-14 | 2016-01-20 | 中央研究院 | 静默egfr表达的脱氧核糖核酸酶 |
JP2019504648A (ja) * | 2016-02-15 | 2019-02-21 | イスティトゥティ クリニシ サイエンティフィシ マウジェリ エスピーエー エスビー | 常染色体優性カテコールアミン誘発性多形性心室頻拍(cpvt)の治療のための対立遺伝子特異的サイレンシングの方法 |
JP2020500518A (ja) * | 2016-11-29 | 2020-01-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ダイナミン2関連疾患のためのアレル特異的サイレンシング療法 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
US8859517B2 (en) | 2011-08-08 | 2014-10-14 | Fondazione Salvatore Maugeri Clinica Del Lavoro E Della Riabilitazione | Method of gene transfer for the treatment of recessive catecholaminergic polymorphic ventricular tachycardia (CPVT) |
CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
EP2872485B1 (en) | 2012-07-13 | 2020-12-16 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
RU2015104762A (ru) | 2012-07-13 | 2018-08-31 | Уэйв Лайф Сайенсес Лтд. | Хиральный контроль |
TW201536329A (zh) * | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
AU2014321211A1 (en) * | 2013-09-23 | 2016-05-05 | President And Fellows Of Harvard College | Allele-specific RNA silencing for the treatment of hypertrophic cardiomyopathy |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
CN109234294B (zh) * | 2015-07-03 | 2022-09-23 | 赣南师范大学 | 一种微生物体内基于脂酰-acp合成脂肪醇乙酸酯的方法 |
CA3022877A1 (en) * | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb |
AU2017229778A1 (en) * | 2016-03-09 | 2018-08-16 | Ionis Pharmaceuticals, Inc. | Methods and compositions for inhibiting PMP22 expression |
KR101872105B1 (ko) * | 2016-09-05 | 2018-06-27 | 사회복지법인 삼성생명공익재단 | 샤르코 마리 투스병 치료용 약학 조성물 |
CN110099999B (zh) * | 2016-12-22 | 2022-12-27 | 南京大学 | 用于听力丧失综合征的动物模型及其治疗方法 |
CN107602670B (zh) * | 2017-09-07 | 2020-03-27 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗ewsr1蛋白rna结合活性的多肽eip-22及其应用 |
WO2020081598A1 (en) * | 2018-10-15 | 2020-04-23 | Flagship Pioneering Innovations V, Inc. | Disrupting genomic complex assembly in fusion genes |
CN110540990B (zh) * | 2019-07-16 | 2024-08-20 | 武汉泽智生物医药有限公司 | 沉默小眼畸形转录因子mRNA表达的siRNA分子 |
CN110420328B (zh) * | 2019-07-19 | 2021-10-29 | 蚌埠医学院第一附属医院 | Syt14抑制剂在制备肺癌治疗药物中的用途 |
CN114605501B (zh) * | 2022-04-07 | 2023-06-30 | 华中科技大学同济医学院附属协和医院 | 一种可拮抗fus蛋白rna结合活性的多肽fip-21及其应用 |
CN116162650B (zh) * | 2022-09-08 | 2024-01-26 | 北京清华长庚医院 | 一种带荧光标签RyR2突变质粒的构建方法及其应用 |
CN117384914A (zh) * | 2023-07-11 | 2024-01-12 | 云南大学 | MhEML4基因克隆及其在种子败育中的应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005096781A2 (en) * | 2004-04-06 | 2005-10-20 | University Of Massachusetts | Methods and compositions for treating gain-of-function disorders using rna interference |
JP2006505288A (ja) * | 2002-11-04 | 2006-02-16 | ユニバーシティー オブ マサチューセッツ | 対立遺伝子特異的rna干渉 |
JP2007531525A (ja) * | 2004-03-31 | 2007-11-08 | ザ ジェネラル ホスピタル コーポレーション | 上皮細胞成長因子受容体ターゲティング治療に対する癌の応答性を決定する方法 |
JP2008504809A (ja) * | 2004-06-04 | 2008-02-21 | ジェネンテック・インコーポレーテッド | Egfr突然変異 |
JP2008546421A (ja) * | 2005-06-28 | 2008-12-25 | ジェネンテック・インコーポレーテッド | Egfrおよびkras変異 |
JP4216266B2 (ja) | 2005-04-15 | 2009-01-28 | 三菱化学メディエンス株式会社 | 高感度な既知変異遺伝子検出方法、およびegfr変異遺伝子検出方法 |
JP2010222847A (ja) | 2009-03-24 | 2010-10-07 | Chugoku Electric Power Co Inc:The | 折畳み式作業台 |
JP2011044347A (ja) | 2009-08-21 | 2011-03-03 | Nisshin Engineering Co Ltd | 二次電池用正極材料の製造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050106731A1 (en) * | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
-
2011
- 2011-09-28 CN CN201180041884.XA patent/CN103080314B/zh not_active Expired - Fee Related
- 2011-09-28 EP EP11829186.3A patent/EP2623600A4/en not_active Withdrawn
- 2011-09-28 JP JP2012536507A patent/JP5996431B2/ja not_active Expired - Fee Related
- 2011-09-28 US US13/821,299 patent/US9238812B2/en not_active Expired - Fee Related
- 2011-09-28 WO PCT/JP2011/072187 patent/WO2012043633A1/ja active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006505288A (ja) * | 2002-11-04 | 2006-02-16 | ユニバーシティー オブ マサチューセッツ | 対立遺伝子特異的rna干渉 |
JP2007531525A (ja) * | 2004-03-31 | 2007-11-08 | ザ ジェネラル ホスピタル コーポレーション | 上皮細胞成長因子受容体ターゲティング治療に対する癌の応答性を決定する方法 |
WO2005096781A2 (en) * | 2004-04-06 | 2005-10-20 | University Of Massachusetts | Methods and compositions for treating gain-of-function disorders using rna interference |
JP2008504809A (ja) * | 2004-06-04 | 2008-02-21 | ジェネンテック・インコーポレーテッド | Egfr突然変異 |
JP4216266B2 (ja) | 2005-04-15 | 2009-01-28 | 三菱化学メディエンス株式会社 | 高感度な既知変異遺伝子検出方法、およびegfr変異遺伝子検出方法 |
JP2008546421A (ja) * | 2005-06-28 | 2008-12-25 | ジェネンテック・インコーポレーテッド | Egfrおよびkras変異 |
JP2010222847A (ja) | 2009-03-24 | 2010-10-07 | Chugoku Electric Power Co Inc:The | 折畳み式作業台 |
JP2011044347A (ja) | 2009-08-21 | 2011-03-03 | Nisshin Engineering Co Ltd | 二次電池用正極材料の製造方法 |
Non-Patent Citations (29)
Title |
---|
AMARZGUIOUI ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 316, 2004, pages 1050 - 1058 |
BASS B.L., CELL, vol. 101, 2000, pages 235 - 238 |
CASTANOTTO D.; ROSSI JJ., NATURE, vol. 457, 2009, pages 426 - 433 |
DAVIS ME ET AL., NATURE, vol. 464, 2010, pages 1067 - 1070 |
DERNBURG, A.F.; KARPEN, G.H., CELL, vol. 111, 2002, pages 159 - 162 |
FURUYA H. ET AL., AMERICAN JOURNAL OF MEDICAL GENETICS PART A, vol. 146A, 2008, pages 459 - 463 |
LI, M-J. ET AL.: "Specific Killing of Ph+ Chronic Myeloid Leukemia Cells by a Lentiviral Vector-Delivered Anti-bcr/abl Small Hairpin RNA.", OLIGONUCLEOTIDES, vol. 13, no. 5, 2003, pages 401 - 409, XP002518237 * |
LYNCH T.J. ET AL., N ENGL J MED, vol. 350, 2004, pages 2129 - 2139 |
MILLER, V. M. ET AL.: "Allele-specific silencing of dominant disease genes.", PROC. NATL. ACAD. SCI. USA, vol. 100, no. 12, 2003, pages 7195 - 7200, XP002278730 * |
NAKAJIMA M. ET AL., JOURNAL OF HUMAN GENETICS, vol. 52, 2007, pages 473 - 475 |
NATARAJAN ET AL., PROC NATL ACAD SCI USA., vol. 104, 2007, pages 17081 - 17086 |
OHNISHI Y. ET AL., JOURNAL OF RNAI AND GENE SILENCING, vol. 2, 2006, pages 154 - 160 |
OHNISHI Y. ET AL., PLOS ONE, vol. 3, no. 5, 2008, pages E2248 |
PAEZ ET AL., SCIENCE, vol. 304, 2004, pages 1497 - 1500 |
PAEZ G.J. ET AL., SCIENCE, vol. 304, 2004, pages 1497 - 1500 |
PAO ET AL., PLOS MEDICINE, vol. 2, no. 3, 2005, pages E73 |
REYNOLDS ET AL., NAT. BIOTECHNOL., vol. 22, 2004, pages 326 - 330 |
SAMBROOK, J.: "Molecular Cloning: a Laboratory Manual Second", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SCHERR, M. ET AL.: "Specific inhibition of bcr-abl gene expression by small interfering RNA.", BLOOD, vol. 101, no. 4, 2003, pages 1566 - 1569, XP002975208 * |
SCHERR, M. ET AL.: "Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.", GENE THERAPY, vol. 21, 2005, pages 12 - 21, XP003015709 * |
See also references of EP2623600A4 |
SHARP P.A., GENES DEV., vol. 15, 2001, pages 485 - 490 |
SHORE EM. ET AL., NATURE GENETICS, vol. 38, 2006, pages 525 - 527 |
SORDELLA, R. ET AL.: "Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways.", SCIENCE, vol. 305, no. 5687, 2004, pages 1163 - 1167, XP002447438 * |
TUSCHL T ET AL., GENES DEV, vol. 13, no. 24, 1999, pages 3191 - 7 |
UI-TEI ET AL., NUCLEIC ACIDS RES., vol. 32, 2004, pages 936 - 948 |
WOHLBOLD, L. ET AL.: "All common p210 and p190 Bcr-abl variants can be targeted by RNA interference.", LEUKEMIA, vol. 19, 2005, pages 290 - 292, XP055070520 * |
YUSUKE ONISHI ET AL.: "RNAi o Mochiita Allyl Tokuiteki Hatsugen Yokusei no Hyoka Hoho no Kakuritsu to Oyo", ANNUAL MEETING OF THE JAPAN SOCIETY OF HUMAN GENETICS PROGRAM-SHOROKUSHU, vol. 54, 2009, pages 145, XP008168243 * |
ZAMORE P.D., SCIENCE, vol. 296, 2002, pages 1265 - 1269 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105264084A (zh) * | 2013-01-14 | 2016-01-20 | 中央研究院 | 静默egfr表达的脱氧核糖核酸酶 |
JP2016504046A (ja) * | 2013-01-14 | 2016-02-12 | ナショナル タイワン ユニバーシティ | Egfrの発現をサイレンシングするためのdnaザイム |
EP2943578A4 (en) * | 2013-01-14 | 2017-01-25 | National Taiwan University | Dnazyme for silencing the expression of egfr |
US9856480B2 (en) | 2013-01-14 | 2018-01-02 | National Taiwan University | Dnazyme for silencing the expression of EGFR |
JP2019504648A (ja) * | 2016-02-15 | 2019-02-21 | イスティトゥティ クリニシ サイエンティフィシ マウジェリ エスピーエー エスビー | 常染色体優性カテコールアミン誘発性多形性心室頻拍(cpvt)の治療のための対立遺伝子特異的サイレンシングの方法 |
JP2020500518A (ja) * | 2016-11-29 | 2020-01-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ダイナミン2関連疾患のためのアレル特異的サイレンシング療法 |
JP2022166236A (ja) * | 2016-11-29 | 2022-11-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ダイナミン2関連疾患のためのアレル特異的サイレンシング療法 |
JP7196071B2 (ja) | 2016-11-29 | 2022-12-26 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ダイナミン2関連疾患のためのアレル特異的サイレンシング療法 |
Also Published As
Publication number | Publication date |
---|---|
EP2623600A4 (en) | 2014-11-26 |
JPWO2012043633A1 (ja) | 2014-02-24 |
US9238812B2 (en) | 2016-01-19 |
JP5996431B2 (ja) | 2016-09-21 |
CN103080314A (zh) | 2013-05-01 |
CN103080314B (zh) | 2016-04-13 |
EP2623600A1 (en) | 2013-08-07 |
US20130197061A1 (en) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5996431B2 (ja) | 優性変異遺伝子発現抑制剤 | |
JP5941842B2 (ja) | 優性アレル発現抑制剤 | |
ES2739804T3 (es) | Compuestos terapéuticos | |
JP2019518772A (ja) | 一本鎖rna編集オリゴヌクレオチド | |
AU2017320901A1 (en) | Chemically modified single-stranded RNA-editing oligonucleotides | |
EP3430143B1 (en) | Inhibitors of srsf1 to treat neurodegenerative disorders | |
TWI752927B (zh) | 具高活性及減低脫靶之siRNA構造 | |
US20210147853A1 (en) | Use of Trinucleotide Repeat RNAs To Treat Cancer | |
US20100086526A1 (en) | Nucleic acid constructs and methods for specific silencing of h19 | |
JP2017518764A (ja) | 癌の処置のための多標的指向RNAi | |
JP6486836B2 (ja) | 遺伝子発現制御のための人工ミミックmiRNAおよびその用途 | |
US20160222386A1 (en) | Nucleic acid molecule for inhibiting activity of rnai molecule | |
JP6137484B2 (ja) | 遺伝子発現抑制用二本鎖核酸分子 | |
JP2009171861A (ja) | 遺伝子発現制御機構を含む新規Adベクター | |
JP2017071572A (ja) | Tdp−43プロテノパシーの予防又は治療用組成物 | |
TW201726919A (zh) | 非對稱干擾rna及其組成物、用途或製備 | |
JP6191980B2 (ja) | RNAi分子活性抑制用核酸の阻害剤 | |
KR102145176B1 (ko) | 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
JP2016192918A (ja) | pre−miRNA又はshRNAの活性を抑制するための核酸分子 | |
Jian et al. | RNA therapy: Are we using the right molecules? | |
JP2013018754A (ja) | 悪性胸膜中皮腫治療剤 | |
JP2006101707A (ja) | 肺癌治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180041884.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11829186 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012536507 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13821299 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2011829186 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011829186 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |